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ABSTRACT 
 Hepatitis C virus (HCV) infects millions of people worldwide and is one of the 
leading causes of liver damage.  Infection with HCV is strongly correlated with an 
increased risk of steatosis, or fatty liver disease, which is caused by a build-up of fat 
deposits in hepatocytes.  All genotypes of HCV appear to cause some degree of steatosis 
in approximately 50% of infected individuals, especially in the presence of contributing 
host factors such as diabetes, obesity and alcoholism.  However, approximately 70% of 
genotype 3a infections exhibit steatosis.  Furthermore, successful clearance of the 
genotype 3a virus results in eradication of the steatosis, suggesting the genotype 3a virus 
may be able to directly cause steatosis.   
 Research suggests a role for the core protein of HCV, which forms the capsid of the 
virus, in the alteration of lipid metabolism pathways during infection.  As such, I 
hypothesized that:  1) HCV alters lipid metabolism pathways and causes the build up of 
lipid in hepatocytes and the development of steatosis; 2) HCV-3a core protein has a 
differential or increased effect on these pathways in comparison to 1b core protein; and 3) 
other HCV proteins could also play a role in the altering of lipid metabolism. 
 The first study characterized the genotype 3a core protein and compared it to 
genotype 1b core.  Very little research had been done on the 3a core protein; I showed 
that it localized to lipid droplets in a similar manner to genotype 1b core protein and that 
mutation of the same residues responsible for lipid droplet localization in 1b core also 
reduced lipid droplet localization in the 3a core protein.  I then examined how the 1b and 
3a core proteins effected the transcriptional activation of Fatty Acid Synthase (FAS), a 
key enzyme involved in the production of triglycerides in hepatocytes.  The 3a core was 
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able to up-regulate transcriptional activity of FAS almost two-fold higher than 1b core.  
When I examined the effect of the lipid droplet localization mutants on FAS up-
regulation, I found a striking difference between the two proteins.  The change of a single  
amino acid at position 164 from a tyrosine in 1b and a phenylalanine in 3a was able to 
dramatically reduce the effect of 3a core on FAS up-regulation when mutated to the 1b 
core amino acid.  This result suggested that this single amino acid may play an important 
role in altering lipid metabolism and causing steatosis to develop, especially in the case 
of genotype 3a infection. 
 My next step was to examine the mechanisms by which genotype 1b and 3a core 
up-regulated FAS.  FAS transcription is mediated by a transcription factor, Sterol 
Response Element Binding Protein-1 (SREBP-1), which also controls the transcription of 
many different genes involved in lipid metabolism.  Activity of SREBP-1 is controlled 
post-translationally by cleavage from a precursor protein to the mature protein that can 
act as a transcription factor.  Processing of SREBP-1 is greatly increased in the presence 
of 3a core protein in comparison to 1b core.  In addition, transcriptional activity from the 
Sterol Response Element (SRE), the binding recognition sequence for SREBP-1, was 
also greatly increased.  Processing of SREBP-1 can be influenced by activity of Akt, an 
important cell signaling kinase.  I found that 1b and 3a core proteins increased the 
phosphorylation of Akt, suggesting that increased activity of Akt may play a role in 
increasing SREBP-1 activity.  When I inhibited Akt activity using a chemical inhibitor, 
LY294002 or Akt VIII, or a dominant negative Akt construct, the transcriptional activity 
from the SRE was significantly decreased in the presence of the core proteins.  This study 
suggests that at least part of the mechanism by which the core proteins increase SREBP-1 
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activity occurs via increased Akt activity. 
 Lastly, I wanted to examine other HCV proteins for a similar effect on SREBP-1 
and FAS.  Very little is known about the function of HCV non-structural protein-2 (NS2) 
and it would be interesting to know if it could influence lipid metabolism. Interestingly, 
NS2 was also able to up-regulate SREBP-1 and FAS transcription via the SRE.  A 
dominant negative mutant of SREBP-1 was able to prevent up-regulation of SREBP-1 
and FAS, suggesting the direct involvement of SREBP-1 on the up-regulation of FAS and 
SREBP-1 by NS2. This study provides an interesting function for the NS2 protein that 
has not been previously shown. 
 The evidence provided in these studies shows a very important role for HCV in 
altering lipid metabolism during infection that may lead to the development of steatosis.  
Current research suggests that the SREBP-1 pathway may be critical in the life cycle of 
the virus and these studies have provided important information on how these pathways 
are being changed by the virus.  Hopefully this work can help identify potential treatment 
options for HCV that can slow down disease progression by preventing the development 
of steatosis or by decreasing viral replication. 
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1.0 INTRODUCTION AND LITERATURE REVIEW 
 
1.1 HEPATITIS C VIRUS CHARACTERISTICS 
 
 Hepatitis C virus is a major causative agent of liver disease worldwide.  An 
estimated 3% of the world’s population are chronic carriers of the virus, including 
approximately 300 000 Canadians.  Each year, 3 to 4 million people are newly infected 
with HCV, primarily through contact with infected human blood by sharing needles in 
intravenous drug use or by contaminated blood transfusions.  Acute infection is most 
commonly asymptomatic but can be accompanied by fatigue and jaundice with 80% of 
infected individuals progressing to a chronically infected state.  Chronic infection is often 
characterized by the development of hepatitis, steatosis, fibrosis and liver cirrhosis 
approximately 20 to 30 years after infection.  Some patients will eventually die of HCV 
due to extensive liver damage, primarily due to the host immune response, or the 
development of hepatocellular carcinoma (HCC).  Currently there is no vaccine for HCV 
and only 54% of HCV infected individuals respond positively to combined therapy of 
pegylated interferon alpha-2b plus ribavirin, depending on HCV genotypic variation and 
other underlying health problems.   Continued HCV research is clearly necessary to 
develop an effective vaccine or antiviral therapy for this devastating disease. 
 
1.1.1 HCV structure 
 
1.1.1.1 Virus particles 
 HCV is an enveloped virus with a positive sense RNA genome in the Hepacivirus 
genus of the Flaviviridae family.  Each virus particle is approximately 55-65 nm in size 
(Kaito et al., 1994; Shimizu et al., 1996).  Electron microscopy (EM) of the virus has 
been hampered by the lack of a cell culture system that produces a sufficient amount of 
2 
virus for visualization.  However, recent work using the JFH-1 cell culture system has 
allowed for further characterization of the virus (Wakita et al., 2005). By examining other 
viruses of the Flaviviridae family, it is believed that HCV has an icosahedral arrangement 
in which the structural glycoproteins E1 and E2 are embedded into a bi-layer lipid 
envelope derived from the host cells.  The core protein forms the nucleocapsid of the 
virus that encloses the RNA genome (Ishida et al., 2001).  There are three forms of the 
virus present in the serum of infected individuals including free virions, immunoglobulin 
associated virions and virions associated with very-low-density and low-density 
lipoproteins (Bradley et al., 1991; Thomssen et al., 1993). 
1.1.1.2 Positive sense RNA genome 
 Hepatitis C virus contains a positive sense, single stranded RNA genome of 
approximately 9.5 kb.  The genome consists of a single open reading frame flanked by 5’ 
and 3’ untranslated (UTR) regions which are important for replication of the genome.  
The highly conserved 5’ UTR is 341 nucleotides long and contains the internal ribosome 
entry site consisting of four major RNA domains with extensive secondary structure.  The 
entire 5’ UTR is believed to be important for IRES activity and HCV translation (Beales 
et al., 2001; Jubin et al., 2000; Lukavsky et al., 2000).  The 3’ UTR is potentially 
important in initiating viral replication.  It consists of a poly (U)/polypyrimidine tract, a 
variable 40 nucleotide sequence, and a highly conserved 98 nucleotide sequence with 
stable secondary structure (Tanaka et al., 1996; Kolykhalov et al., 1996). 
1.1.1.3 HCV genotypes and quasispecies 
 The discovery of HCV was unique in that the existence of the virus was 
confirmed using molecular cloning techniques rather than direct biological methods.  The 
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viral sequence was first obtained by extracting all nucleic acid from the serum of a non-A 
non-B hepatitis infected chimpanzee, creating cDNA clones and identifying the clone 
corresponding to the HCV genome (Choo et al., 1991). Using these methods, different 
strains of HCV were indentified and categorized into at least six major genotypes based 
on nucleic acid sequence alone.  Genotypes are approximately 65% identical across the 
whole HCV genome.  Within each genotype, subtypes are also evident with 
approximately 80% nucleic acid similarity (Simmonds et al., 1994). The different 
genotypes have different geographical distributions and prevalence, with genotype 1 
being the most prevalent genotype in North America and Europe while genotype 4 is 
most common in Egypt and North Africa and genotypes 5 and 6 are most common in 
South Africa and Hong Kong.  Genotypes 2 and 3 are common in North America, Europe 
and Japan, but to a lesser extent than genotype 1.  A high number of subtypes are evident 
in Africa and Southeast Asia, suggesting that this region may be the original source of 
HCV as fewer subtypes are evident in Europe and North America (Smith and Simmonds, 
1997). Currently, genotyping of the virus in an infected individual is accomplished by 
DNA hybridization, restriction length fragment polymorphism, direct nucleotide 
sequencing using polymerase chain reaction, and serologic genotyping.  Many of the 
current methods, excluding direct nucleotide sequencing, cannot discriminate between 
viral subtypes.  
 It has become very clear that the HCV genotype is clinically relevant.  In acute 
infection, the rate of progression to chronic infection has been related to genotype, with 
an increased number of genotype 1 infected individuals progressing to chronicity in 
comparison with other genotypes (Amoroso et al., 1998). Perhaps more importantly, 
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treatment response rates to combination therapy are directly correlated with HCV 
genotype.  Genotype 1 or 4 infected individuals will only respond to treatment 
approximately 40-50% of the time, and only with a longer course of therapy than 
genotype 2 and 3 infected individuals who are able to clear the virus in approximately 70 
to 80% of cases with a shorter treatment duration.  The reason for this dramatic difference 
between genotypes is largely unknown, but may be related to an interferon sensitivity-
determining region in the NS5a protein (Enomoto et al., 1995; El-Shamy et al., 2008; 
Torres-Puente et al., 2008). 
 Interestingly, HCV genotype has also been correlated with the development of 
steatosis in HCV infected individuals.  Several studies have shown that a substantially 
increased number of HCV genotype 3a infected patients have steatosis, even in the 
absence of contributing factors such as obesity, diabetes and alcoholism.  Furthermore, 
steatosis is abolished upon successful treatment and clearance of the virus, suggesting 
that HCV genotype 3a may play a direct role in altering hepatic lipid metabolism that is 
not as evident with other genotypes. 
 Within each HCV infected individual, many different sequences of the virus exist 
which are 90-99% identical at the nucleotide level and are members of the same infecting 
genotype.  These populations of virus, called quasispecies, are generated by the error-
prone nature of the HCV RNA-dependent RNA polymerase during genomic replication. 
These quasispecies populations exists in high numbers during acute infection; as infection 
progresses, the number of dominant quasispecies populations decreases with the major 
quasispecies strain changing intermittently.  The role of these quasispecies populations is 
two fold.  Firstly, high mutation rates can result in the development of new viral strains 
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that have increased viral fitness over the parent strain.  Secondly, viral quasispecies likely 
serve as a mechanism for immune evasion and viral persistence.  As the immune system 
mounts an antibody response against a particular viral epitope, the virus quickly mutates 
and the dominant viral population changes to one that the immune system no longer 
recognizes.  In a similar fashion, the virus can also quickly generate mutants that are 
resistant to antiviral drugs.  The high mutability of the HCV virus poses several 
challenges to the development of an effective vaccine or antiviral drug.  
1.1.2 HCV proteins 
 The HCV genome is translated into a polyprotein that is subsequently cleaved into 
approximately 10 proteins in the sequence Core-E1-E2-p7-NS2-NS3-NS4a-NS4b-NS5a-
NS5b.  The Core, E1, E2 and p7 proteins are considered structural proteins of the virus 
while NS2, NS3, NS4a, NS4b, NS5a and NS5b are non-structural proteins. 
1.1.2.1 Structural proteins 
 The core protein is cleaved from the polyprotein via host signal peptidase to form 
a 191 amino acid immature form of the protein.  The core protein is then cleaved between 
amino acids 173 to 179 by host Signal Peptide Peptidase (SPP) to form the mature protein 
(Okamoto et al., 2004).  The core protein is a dimeric alpha-helical protein that can bind 
RNA and consists of two major domains.  The D1 domain is primarily hydrophilic and is 
located in the N-terminus while the D2 domain is primarily hydrophobic and located in 
the C-terminus.  D2 assists in the folding of the protein as well as membrane and lipid 
droplet association (Boulant et al., 2005; Santolini et al., 1994). The core protein is 
localized on the endoplasmic reticulum and on the surface of lipid droplets in infected 
cells.   Some studies have also shown a small amount of core protein in the nucleus and 
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on mitochondria, but this localization has not been observed in infected cells 
(McLauchlan, 2000; Hope et al., 2002; Suzuki et al., 2005; Rouille et al., 2006).  
Localization of core with lipid droplets is also mediated by proteolytic cleavage by SPP 
(McLauchlan et al., 2002). Mature core proteins form the nucleocapsid of the virus. 
However, many studies have shown alternative roles for the core protein in the 
pathogenesis of HCV including apoptosis, insulin resistance, cell cycle, and lipid 
metabolism.  Interestingly, the core protein-encoding region also contains a +1 alternative 
reading frame that results in translation of the ARF (alternative reading frame) protein.  
The F protein does not contain an AUG start codon, so translation of this protein is a 
random event.  No known function of the F protein is currently known. Although 
antibodies against it are present in HCV infected individuals, it is not required for viral 
replication (Branch et al., 2005). 
 The E1 and E2 proteins of HCV are envelope glycoproteins that are essential for 
virus entry and form heterodimers on the viral envelope.  The E2 protein contains a 
hypervariable region that mutates frequently to allow for the development of immune 
escape variants (Forns et al., 2000; Callens et al., 2005). 
 The p7 protein has recently been found to have ion-channel activity and it is 
essential for virus infectivity.  As such, new research has been directed toward 
developing antiviral compounds to block the function of this protein (Saint et al., 2009). 
1.1.2.2 Non-structural proteins 
 The NS2 protein is a hydrophobic protease that cleaves the HCV polyprotein 
between NS2 and NS3 and it may function as a novel cysteine protease. Efficient 
cleavage of NS2/3 is required for HCV replication, but the presence of NS2 is not 
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required for genome replication.  Following cleavage, NS2 is localized in the ER 
membrane.  Besides its protease activity, NS2 appears to be involved in apoptosis, cell 
proliferation, innate immunity and lipid metabolism (Dumoulin et al., 2003; Erdtmann et 
al., 2003; Yang et al., 2006; Oem et al., 2007). 
 The NS3 protein is a protease and RNA helicase.  Protease activity of NS3 is 
mediated by the NS4a protein.  Both proteins are localized on the ER.  The NS3/4a 
protease complex cleaves the HCV polyprotein downstream of NS3 and this action is 
essential for formation of the viral replication complex (Lindenbach et al., 2005). NS3/4a 
is able to inhibit the host innate immune response via disrupting the RNA helicase 
retinoic acid-inducible gene-I (RIG-I) pathway by cleaving Cardif, an adaptor protein of 
interferon regulatory factor-3  (Foy et al., 2003).  The function of the NS3/4a helicase 
activity is still unknown. 
 The NS4b protein is present on the ER membrane and induces intracellular 
membrane changes that may be involved in the formation of the replication complex 
membranous webs (Hugle et al., 2001; Egger et al., 2002). It also contains a nucleotide 
binding motif that hydrolyzes GTP (Einav et al., 2004).  NS4b is thought to play a major 
role in viral replication, assembly and release as well as lipid metabolism (Jones et al., 
2009; Park et al., 2009). 
 NS5a is also an ER-associated protein that is particularly multi-functional.  It can 
bind to HCV RNA and it is essential for viral replication (Huang et al., 2005).  It can be 
hyperphosphorylated in order to inhibit viral replication (Evans et al., 2004).  NS5a is 
also able to decrease the immune response via inhibition of interferon-induced double 
stranded RNA activated protein kinase PKR (Gale et al., 1998).  NS5a may also play a 
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role in mediating lipid metabolism as it interacts with core proteins on the surface of lipid 
droplets and it also interacts with apolipoproteins (Shi et al., 2002). 
 NS5b is an RNA dependent RNA polymerase that synthesizes RNA using an 
RNA template.  It is also localized on the ER membrane and it is essential for viral 
replication.  As such, it is a prime target for the development of antiviral compounds 
(Lohmann et al., 2000). 
1.1.3 HCV life cycle 
1.1.3.1 Receptors and entry 
 The entry of HCV into a naïve host cell appears to be a complicated, multi-step 
process involving several different host receptors.  The initial entry steps have only been 
recently characterized thanks to the newly developed infectious cell culture system, and 
many details are still to be discovered.  Heparin, a glycosaminoglycan, has been long 
suspected to play a role in viral entry with several studies showing inhibition of viral 
attachment in the presence of heparinase, an enzyme that disrupts heparin (Koutsoudakis 
et al., 2006; Barth et al., 2003; Barth et al., 2006). Low-density lipoprotein receptor 
(LDLR) is very likely a critical component of viral attachment.  HCV in the serum of 
infected patients is bound to low density and very low-density lipoproteins.  Adsorption 
of HCV from the serum of infected patients can be inhibited through the use of antibodies 
against LDLR suggesting that the association of HCV with lipoproteins is an important 
step in attachment of the virus (Thomssen et al., 1992; Andre et al., 2002; Huang et al., 
2007a; Monazahian et al., 1999; Molina et al., 2007).  CD81, a cell surface protein in the 
tetraspanin family, is considered one of the major players in HCV attachment.  
Antibodies against CD81 effectively inhibit HCV infectivity in different models. In 
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addition, HepG2 and HH29 hepatoma cells, which are not normally permissive to HCV 
infection, can be infected following ectopic expression of CD81 (Cormier et al., 2004; 
Wakita et al., 2005.  However, expression of CD81 in other non-permissive cell lines 
does not allow HCV infection to occur, suggesting that other host cell factors may be 
involved in the attachment and entry process (Bartosch et al., 2003). Scavenger receptor 
class B type I (SR-BI) is another cell surface protein that may be involved in viral 
attachment and entry.  SR-BI is a receptor for lipoproteins and it can also change the lipid 
composition of membranes.  Blocking of SR-BI with antibodies can prevent virus entry.  
It is still unclear whether SR-BI is interacting directly with the virus proteins or if it is 
interacting with virus associated lipoproteins to mediate virus entry as both mechanisms 
have been observed (Bartosch et al., 2003; Catanese et al., 2007; Acton et al., 1996; 
Maillard et al., 2006; Huang et al., 2003).  Recently, two tight junction cell proteins 
Claudin-1 and Occludin have been shown to be involved in HCV entry.  Claudin-1 can be 
ectopically expressed in non-permissive, non-hepatic 293T cells and allow HCV infection 
to occur.  Knock-down of Claudin-1 in permissive Huh7 cells can reduce HCV 
infectivity.  It has also been found that Claudin-1 and Occludin are involved in late entry 
of the virus into the cell, which likely occurs through interaction with the tight junctions  
(Evans et al., 2007). The use of the tight junctions by HCV may also allow for cell to cell 
spread of the virus (Timpe et al., 2008). 
It has been shown that HCV entry is mediated by endocytosis in a pH-dependant 
manner.  In addition, knock-down of clathrin, a critical component of the endocytotic 
vesicles, prevents HCV infection (Meertens et al., 2006; Blanchard et al., 2006).  Fusion 
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of the virus envelope with the endosome membrane is not well characterized and both E1 
and E2 are likely involved in the process (Lavillette et al., 2007). 
1.1.3.2 Replication, assembly and release 
 HCV replication occurs in a membrane associated replication complex that 
contains several viral and host proteins and replicating RNA.  The positive strand of the 
virus RNA genome is made into a negative strand that is then used to make more positive 
strand copies for packaging.  The NS5b protein is the major player in the synthesis of 
both the positive and negative strands. The HCV replication complex appears to contain a 
membrane alteration called a membranous web that can be observed by electron 
microscopy in infected cells in vitro and in vivo, as well as in cells expressing the NS4b 
protein alone. The source of the membranous web is likely the ER as most of the HCV 
proteins are associated with the ER upon translation (Shi et al., 2003; Gosert et al., 2003).  
It is also possible that viral replication is occurring on lipid rafts that contain large 
amounts of cholesterol and sphingolipids.  Inhibitors of sphingolipid synthesis can 
prevent HCV replication and both non-structural proteins and replicating RNA are found 
on lipid rafts (Sakamoto et al., 2005; Matto et al., 2004; Aizaki et al., 2004; Shi et al., 
2003).  Recently, it has been determined that lipid droplets play an important role in virus 
assembly.  Core protein localizes around lipid droplets where it recruits non-structural 
proteins and replication complexes.  Inhibiting lipid droplet localization of core protein 
decreased the production of infectious virus particles (Miyanari et al., 2007).  There are 
also many different host cell proteins with putative roles in HCV replication.  For 
example, vesicle-associated membrane protein-associated proteins A and B (VAP-A and 
VAP-B) localize in the ER and bind both NS5a and NS5b and are essential for viral 
11 
replication (Hamamoto et al., 2005). Cyclophilin B, a peptidyl-prolyl cis-trans isomerase, 
binds to NS5b and enhances its RNA binding activity (Watashi et al., 2005).  Similarly, 
p68, and RNA helicase, binds NS5b and moves into the cytoplasm from the nucleus to 
assist in viral replication (Goh et al., 2004). 
 Very little is known about HCV assembly and release.  There are several different 
forms of the virus found in infected serum, including free mature virions, virions bound 
to low-density and very low-density lipoproteins, virions bound to immunoglobulins and 
non-enveloped nucleocapsids.  It is believed that viral RNA can interact with the core 
protein, which then oligomerizes to form the nucleocapsid around the viral RNA (Tanaka 
et al., 2000).  The envelope of the virus is then obtained through core interaction with E1 
glycoprotein on the ER membrane, from which budding occurs (Ezelle et al., 2002; 
Murakami et al., 2006). From this point it is thought that the virus is released from the 
cell after transit through the Golgi apparatus and the secretory pathway (Serafino et al., 
2003). 
1.1.3.3 Virus-like particles 
 In the serum of HCV infected individuals, several different forms of HCV can be 
found that differ in both size and density.  Currently very little is known about HCV 
assembly and how these different types of HCV particles are formed and secreted. HCV 
RNA can be found in infected serum at a density between 1.03 and 1.25 g/ml (Thomssen 
et al., 1992; Thomssen et al., 1993).  Interestingly, the lower density particles appear to 
be more infectious than the higher density particles when tested in chimpanzees (Bradley 
et al., 1991; Hijikata et al., 1993).  The low-density particles contain high amounts of 
triglycerides, as well as HCV RNA, core protein and apolipoproteins B and E (ApoB and 
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ApoE).  Triglycerides along with ApoB and ApoE are the major components of very-low 
density lipoproteins (VLDL) and low-density lipoproteins (LDL) which are particles 
packaged in the ER of hepatocytes to be secreted into the bloodstream and transport their 
triglyceride load to adipocytes for storage (Rustaeus et al., 1999). During HCV infection, 
assembled virus particles are hypothesized to use this pathway to acquire ApoB, ApoE 
and triglycerides prior to secretion from the cells.  Virus particles that do not obtain the 
necessary triglycerides and apolipoproteins are not secreted from the cell and undergo 
degradation.  Exploitation of the VLDL assembly pathway by HCV ultimately decreases 
lipid export from the cells and could be an important factor in the development of 
steatosis in infected patients.  The addition of apolipoproteins and triglyceride to the virus 
particle could also be advantageous to the virus as it could be providing a mechanism of 
immune escape by hiding viral epitopes and also by increasing the number of potential 
receptors (ie. CD81, LDLR and SR-BI) for attachment (Gastaminza et al., 2008; Huang et 
al., 2007a; Nielsen et al., 2006; Andre et al., 2002; Perlemuter et al., 2002). 
 Another fraction of the HCV population in infected serum appears to be non-
enveloped.  These particles have a higher density and vary in size.  The core protein is 
displayed on the surface of these particles and antibodies against core protein are a 
hallmark of HCV infection.  Currently it is unknown whether these nonenveloped 
particles are infectious or what role they play in the course of HCV infection and 
pathogenesis (Maillard et al., 2001). 
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1.1.4 HCV molecular pathogenesis 
1.1.4.1 Cell survival and apoptosis 
 Apoptosis is a very important mechanism for the removal of virus infected cells 
and many viruses inhibit apoptotic pathways in order to ensure their continued survival.  
However, in chronic HCV infection an increased amount of apoptosis is observed in the 
liver although it is unknown whether HCV infected or uninfected hepatocytes are 
undergoing apoptosis (Calabrese et al., 2000; Bantel et al., 2001). Three major death 
ligands, CD95 Ligand, Tumor Necrosis Factor α (TNFα) and Tumor Necrosis Factor 
Related Apoptosis Inducing Ligand (TRAIL), are considered to be the major players in 
inducing hepatocyte apoptosis. Infection with HCV up-regulates all three of these death 
ligands.  In addition, CD95 Ligand induced apoptosis was observed in uninfected 
bystander cells of HCV infected livers  (Calabrese et al., 2000; Ghavami et al., 2005; 
Ando et al., 1997; Gremion et al., 2004).  Interestingly, TRAIL can also induce the 
development of steatosis (Mundt et al., 2005).  When specific HCV proteins were 
examined for their influence on apoptosis, results showed that all HCV proteins have 
both pro-apoptotic and anti-apoptotic effects depending on the model being used and it is 
currently unclear as to what occurs in vivo.  Core proteins have been shown to inhibit 
TNFα and CD95 Ligand induced apoptosis in cell culture, while other studies have 
shown that the presence of core protein, including those expressed in transgenic mice, 
cannot inhibit CD95 Ligand induced apoptosis (Ray et al., 1998; Ruggieri et al., 1997; 
Machida et al., 2001). Core proteins can directly interact with several pro-apoptoic 
proteins including CD95, TNF-R1 and lymphotoxin-β (Zhu et al., 1998; Matsumoto et 
al., 1997).  However, it can also bind to FADD, C-FLIP and Smad3 to prevent apoptosis  
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(Saito et al., 2006; Pavio et al., 2005).  Core can also increase phosphorylation of Akt, an 
important protein involved in cell survival (Waris et al., 2007).  Core proteins also induce 
oxidative stress that can lead to increased susceptibility to apoptosis (Okuda et al., 2002; 
Machida et al., 2006). The E1 protein inhibits TRAIL-induced apoptosis, while E2 can 
induce caspase dependent apoptosis (Lee et al., 2007; Chiou et al., 2006).  NS2 can 
inhibit CIDE-B induced apoptosis, while NS3 can cleave Cardif and prevent RIG-I 
associated apoptosis  (Erdtmann et al., 2003; Meylan et al., 2005).  NS4a can induce 
caspase-8 independent apoptosis from the mitochondria (Nomura-Takigawa et al., 2006).  
NS5a has shown both anti-apoptotic and pro-apoptotic effects.  It can inhibit Bax-
mediated apoptosis by acting as a bcl-2 homologue. It can also activate the PI3K/Akt 
pathway and prevent p53- mediated apoptosis (Chung et al., 2003; Lan et al., 2002; Street 
et al., 2004).  However, direct apoptosis has been observed in cells expressing NS5a 
(Macdonald et al., 2004).  All of these results suggest an important but complex role of 
HCV and its proteins in mediating cell survival and apoptosis that is yet to be fully 
explained.  The anti-apoptotic potential of this virus may influence the development of 
hepatocellular carcinoma, a common complication of HCV infection (Balsano and Alisi, 
2007). 
1.1.4.2 Immunopathogenesis 
 It is generally accepted that liver damage during HCV infection is primarily 
caused by the reaction of the immune system to virus infection, although some cytopathic 
effects of the virus such as increased apoptosis and the development of steatosis have 
been observed.  HCV itself has also been shown to alter both the innate and adaptive 
immune responses.  The NS3/4a protease is able to induce cleavage of mitochondrial 
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antiviral signaling protein (MAVS), which results in the impairment of RIG-I mediated 
interferon production in the presence of dsRNA (Meylan et al., 2005). During viral 
infection, cytotoxic lymphocytes are critical to the efficient removal of infected cells.  In 
acute HCV infection, the appearance of HCV specific cytotoxic CD8+ T cells (CTLs) is 
associated with decreased viremia  (Shoukry et al., 2003). Activation of HCV specific 
CD38+ CD69+ T cells coincides with inflammation and hepatitis during acute infection, 
suggesting a role for these non-interferon γ producing CTLs in causing immune mediated 
liver damage (Lechner et al., 2000). Regulatory T cells have been shown to have an 
important role in suppressing HCV-specific CTL responses, as increased numbers of 
regulatory T cells are present in chronically infected patients versus those who have 
spontaneously recovered from their infection (Cabrera et al., 2004).  Therefore, it is likely 
that CTLs play a role in both controlling viremia and causing liver damage during HCV 
infection. 
 Natural Killer (NK) cells are also important lymphocytes involved in clearing 
viral infection.  NK cells can directly or indirectly induce apoptosis in virally infected 
hepatocytes that may contribute to both viral clearance and liver damage.  HCV infected 
cells have decreased MHC class I protein expression, which is a primary inducer of NK 
mediated cell lysis.  Conversely, NK cells may actually protect the liver from progression 
to fibrosis by removing activated hepatic stellate cells, the main fibrogenic cell type in the 
damaged liver.  Indeed, increased NK cytolytic activity is inversely correlated with the 
fibrosis stage in the liver (Morishima et al., 2006). 
 γδ T cells are also important lymphocytes in the liver during viral infection.  
Increased levels of γδ T cells are present in the livers of chronic HCV patients (Tseng et 
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al., 2001). However, γδ T cells have also been shown to have a protective effect on the 
liver during chronic viral infection, suggesting that they too may also decrease liver 
injury during infection (Fu et al., 1994). 
1.1.4.3 Lipid metabolism 
 One of the major functions of the liver is to metabolize lipids.  As such, infection 
of hepatocytes with HCV is likely to affect cellular pathways involved in lipid 
metabolism.  Indeed,  patients infected with HCV show clinical disease associated with 
lipid metabolism defects such as steatosis and hypolipoproteinemia (Serfaty et al., 2001).  
In vitro studies have also demonstrated an important role for the virus in exploiting lipid 
metabolism pathways in order to produce virus particles and evade the immune system 
that contribute to HCV pathogenesis (Ye, 2007). These pathways will be discussed in 
further detail in section 1.4. 
1.2 HCV CLINICAL CHARACTERISTICS 
1.2.1 Acute viral infection 
 Upon infection with HCV, most patients enter an acute phase that is largely 
asymptomatic.  Most of the infected individuals (~80%) will progress to chronic HCV 
infection while the other 20% will clear the virus within the first 3 months after infection.  
The asymptomatic nature of the acute stage of infection results in difficulty in diagnosing 
and reporting HCV infection, as well as difficulty in studying the aspects of the immune 
response that allow for viral clearance during this time.  The greatest risk of infection 
with HCV is through intravenous drug use, unprotected sex, exposure during medical 
procedures, vertical transmission from mother to child, or needle injury in health care 
professionals.  Blood transfusion prior to 1992 is also an important risk factor (Centers 
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for Disease Control and Prevention. Surveillance for acute viral hepatitis United States, 
2005.  56th ed. Atlanta, GA: Centers for Disease Control and Prevention; 2007. P. 1-24). 
HCV RNA can be detected in the serum approximately 1-3 weeks after exposure.  
Symptoms include fatigue, jaundice, dyspepsia, and abdominal pain but are generally not 
specific or severe enough to warrant consultation of a doctor.  Elevated alanine 
aminotransferase (ALT) levels can be detected 4-12 weeks after exposure and are the first 
indication of liver injury  (Santantonio et al., 2003).  Serum HCV RNA and anti-HCV 
antibody seroconversion is generally used to detect HCV infection (Pawlotsky, 2002).  
Host and viral factors appear to contribute to viral clearance in acute infection including 
genotype of the virus, HIV co-infection, gender, race, age and HLA (Lehmann et al., 
2004).  A strong cellular immune response is also thought to increase viral clearance, and 
symptomatic infection appears to correlate with viral clearance (Gruner et al., 2000; 
Thimme et al., 2001).  Patients who spontaneously clear the virus need to be monitored as 
disease relapse may occur up to 6 months after clearance (Gerlach et al., 1999). 
1.2.2 Chronic viral infection 
 Infection with HCV is one of the leading causes of liver disease worldwide.  As 
previously discussed, a small proportion of people are able to clear the virus following an 
acute infection but the majority progress to a chronically infected state.  Chronic infection 
can persist for many years without causing the death of the patient.  However, most cases 
eventually lead to the development of hepatitis, fibrosis, steatosis and cirrhosis with the 
eventual need for a liver transplant if left untreated.  A small number of HCV infected 
individuals will also develop hepatocellular carcinoma.  Host factors such as age, obesity, 
alcohol use, gender, race and co-infection with HIV or HBV can increase the rate of 
18 
progression of liver damage (Soto et al., 1997; Pontisso et al., 1998; Corrao and Arico, 
1998).  Genotype does not appear to play a role in disease progression (Silini et al., 
1996).  However, the presence of non-alcoholic steatohepatitis can increase progression 
of disease, and infection with genotype 3a is associated with a higher prevalence of 
steatosis  (Mihm et al., 1997; Adinolfi et al., 2001).  In general, the rate of progression to 
cirrhosis is unpredictable in chronic HCV infection (Ascione et al., 2007). 
1.2.3 Associated clinical pathology 
1.2.3.1 Hepatitis, steatosis, fibrosis and cirrhosis 
 As previously discussed, HCV is not generally considered to be a cytopathic 
virus.  Damage to the liver is thought to be primarily the result of immunopathogenic 
mechanisms.  However, HCV has been associated with direct cytopathic effects on the 
liver such as apoptosis, stellate cell activation, the development of steatosis and insulin 
resistance.  Damage to the liver is clinically observed by increased ALT levels. In the 
case of HCV, liver biopsies are often taken to assess the stage of liver disease.  Hepatitis 
of the liver occurs following an infiltration of inflammatory cells into the liver and 
damage of the hepatocytes leads to steatosis and fibrosis.  Steatosis of the liver is the 
accumulation of lipid within hepatocytes that can eventually lead to the development of 
fibrosis.  Fibrosis of the liver is characterized by the accumulation of extracellular matrix 
proteins, like collagen, that are produced by different liver cell types following damage.  
Liver fibrosis can be reversed  (Bataller and Brenner, 2005).  Cirrhosis is the final stage 
of liver disease in which liver tissue is replaced by scar tissue and nodules that decrease 
liver function.  Cirrhosis is irreversible and patients in the advanced stages of liver 
cirrhosis will need a liver transplant (Mengshol et al., 2007). 
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1.2.3.2 Lymphoproliferative disorders 
 One of the best characterized extra-hepatic disorders associated with HCV 
infection is mixed cryoglobulinemia (MC).  MC is caused by the development of 
cryoglobulins consisting of polyclonal IgG and monoclonal IgM or polyclonal IgM with 
rheumatoid factor that precipitate in the blood at less than 37°C (Zignego 1997).  
Symptoms include weakness, arthralgias, and palpable purpura in the lower extremities 
and complications can include kidney damage and possibly liver damage (Ferri 1992; 
Kayali 2002; Saadoun 2006).  Approximately 5-10% of HCV patients exhibit MC (Lunel 
1994).  Successful treatment of the HCV infection results in eradication of MC in most 
patients (Zignego 2007b).  HCV is also associated with malignant lymphomas that may 
be related to MC.  B-cell derived Non-Hodgkin’s Lymphoma is the most common 
lymphoma associated with HCV infection (De Vita 1997). 
1.2.3.3 Hepatocellular carcinoma 
 Infection with HCV is a major risk factor for the development of hepatocellular 
carcinoma (HCC).  The mechanism by which HCV causes HCC is unknown but several 
studies have indicated a role for the core protein, including the induction of oxidative 
stress and steatosis.  Cellular signaling pathways are also changed by the core protein, as 
previously discussed.  The development of liver fibrosis and cirrhosis also increases the 
risk for HCC.  Approximately 1-3% of HCV patients will develop HCC after 30 years of 
chronic infection  (Hassan et al., 2002).  Age, alcohol consumption, obesity, diabetes, 
genotype and co-infection with HBV or HIV can all increase the risk of developing HCC 
in HCV infected patients (El-Serag, 2002). 
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1.2.4 Treatment 
1.2.4.1 Ribavirin and interferon combination therapy 
 The current standard of treatment for HCV is a combination therapy of pegylated 
interferon α with ribavirin.  Treatment is generally successful in eradicating the virus in 
approximately 50% of genotype 1 patients and 80% of genotype 2 and 3 patients.  
Treatment duration is 48 weeks in genotype 1 infection and only 24 weeks or even less in 
genotype 2 and 3 infection.  Sustained Virological Response (SVR) is determined by 
undetectable HCV RNA levels 24 weeks after the end of treatment; the large majority of 
patients who achieve SVR remain virus free and have reduced liver damage (Zeuzem, 
2008).  Interferon α is a non-specific antiviral agent that acts by inducing 2’, 5’ –
oligoadenylate synthetase, double stranded RNA activated protein kinase and myxovirus 
proteins.  It may also indirectly enhance the function of NK cells, CTLs and macrophages  
(Chevaliez and Pawlotsky, 2007).   
The mechanism of action of ribavirin is largely unknown.  Studies have shown a 
potential involvement in modulating the immune response, inhibiting inosine 
monophosphate dehydrogenase, directly inhibiting HCV NS5B, inducing mutagenesis, 
and modulating interferon-stimulated gene expression (Hofmann et al., 2008). New 
protocols for treatment doses and duration are constantly being updated.  
1.2.4.2 Anti-viral drugs 
 There are currently several HCV-specific antivirals going through clinical trials.  
Antiviral drugs are being developed to target the NS3/4a protease; these antivirals include 
telaprivir and boceprivir.  In phase 3 clinical trials both of these antivirals can increase 
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Sustained Virological Response (SVR) rates in genotype 1 patients when used in 
combination with interferon α and ribavirin (Dusheiko et al., 2008; Schering Plough  
http://www.schering-
plough.com/Schering_plough/news/release.jsp?releaseID=1182855).  Monotherapy with 
these antivrals is unlikely due to the rapid development of resistant mutants following 
treatment.  R1626, a nucleoside inhibitor of the HCV NS5b, has been shown to reduce 
viral load when used in combination with interferon α and ribavirin  (Roberts et al., 
2008).  It is likely that future treatment for HCV will include antivirals in combination 
with standard interferon α/ ribavirin therapy and that this strategy will significantly 
increase SVR rates. 
1.2.4.3 Vaccines 
 Vaccine development for HCV has been hampered by several issues. Currently, 
the role of neutralizing antibodies, the hallmark of most vaccines, in clearing HCV 
infection is undetermined largely due to the limited ability to grow the virus in cell 
culture and also the highly variable genome of the virus.   However, it is clear that helper 
and cytotoxic T cell responses play an important role in viral clearance.  Keeping this in 
mind, several avenues are being pursued for an effective HCV vaccine candidate.  These 
include:  1) a vaccine that will prevent infection (ie. prophylactic); 2) a vaccine that 
would enhance viral clearance following infection; or 3) a vaccine that would induce viral 
clearance when given during chronic infection (ie. therapeutic).  Several different vaccine 
candidates are currently in clinical trials although none have been approved for use 
(Strickland et al., 2008). 
 
22 
1.3 HCV EXPERIMENTAL MODELS 
1.3.1 Replicon cells 
 Up until 1999, one of the only methods available to examine HCV pathogenesis 
and infection in vitro was by transiently transfecting HCV genes, alone or in 
combination, into different cell types. This method is straightforward and effective and 
allows for the examination of the effects of a single HCV protein on a cell.  However, 
transient transfection of DNA is not the most accurate model to study the effects of an 
RNA virus in vitro.  Unfortunately, attempts at establishing a robust HCV cell culture 
system had been unsuccessful and so the various aspects of the HCV life cycle could not 
be examined.  As such, the development of the HCV replicon system by Lohmann et al. 
provided a new and important model to study HCV pathogenesis and replication 
(Lohmann et al., 1999). 
 Using previous protocols established with Bovine Viral Diarrhea Virus (BVDV) 
and Kunjin, two members of the Flaviviridae family, a subgenomic molecular clone of 
genotype 1b HCV was developed that contained the 5’UTR, a neomycin resistance 
cassette, the ECMV IRES and the HCV NS3 to 3’UTR region.  Once transcribed into 
RNA, the subgenomic replicon construct was electroporated into Huh7 human hepatoma 
cells and stably transfected cells were selected using G418.  Expression of HCV proteins 
and replication of the HCV subgenome was confirmed (Lohmann et al., 1999).  This 
system has since been used to develop genomic replicons that, for as yet unknown 
reasons, do not assemble and produce infectious virus particles (Ikeda et al., 2002). 
Further optimization of this procedure has allowed it to become a very critical component 
of HCV research, although some aspects of the HCV life cycle such as entry and 
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assembly cannot be studied.  In addition, Huh7 cells appear to be the only cell line to 
permit high levels of replication of the replicon, although other cell lines can support low 
levels of replication (Uprichard et al., 2006; Ali et al., 2004; Zhu et al., 2003).  Another 
interesting aspect of the replicon system is that certain regions of the replicon subgenome 
mutate in order to adapt to cell culture and replicate efficiently, and these mutations could 
partially explain the difficulty in infecting cells in culture with a wild type strain  
(Lohmann et al., 2001; Krieger et al., 2001). 
1.3.2 JFH-1 infectious cell culture system 
 The most important development in HCV research in recent years has been the 
discovery of the JFH-1 strain.  The JFH-1 virus was isolated from a patient with 
fulminant hepatitis and identified as genotype 2a, although with some novel mutations.  
Kato et al. cloned the JFH-1 virus into a subgenomic replicon and examined its 
replication in several different cell lines.  Surprisingly, the subgenomic JFH-1 replicon 
replicated at a much higher level than other previously utilized replicons.  In addition, 
JFH-1 could also replicate in cell lines other than Huh-7 and no adaptive mutations 
appeared in the replicon expressing cell lines (Kato et al., 2001; Kato et al., 2003).  To 
further examine JFH-1, a full-length genomic construct was made.  Following 
electroporation of the full-length JFH-1 construct, Huh7 cells were able to produce 
infectious virus particles, although at a low titre.  These particles could infect naïve Huh7 
cells as well as a chimpanzee, proving its validity as an experimental model (Wakita et 
al., 2005; Zhong et al., 2005). Subsequent work by many groups have improved the JFH-
1 cell culture system by creating chimeric viruses with other HCV genotypes or viruses 
with mutations that improve viral replication and particle production  (Kato et al., 2007; 
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Yi et al., 2006; Scheel et al., 2008; Gottwein et al., 2007).  The HCV cell culture system 
will continue to provide a wealth of information on the HCV life cycle. 
1.3.3 Animal models  
1.3.3.1 Chimpanzees 
 Chimpanzees are the most important animal model available for HCV research.  
No other animal can be successfully infected with HCV and develop a disease that 
closely resembles that of human HCV infection.  In chimpanzees, HCV infection 
proceeds in much the same way as in humans, with many animals developing a chronic 
infection, although symptoms are milder.  Acute infection can also be studied in 
chimpanzees as this is often difficult in humans due to the non-specific nature of the 
symptoms.  Immune responses to HCV can also be assessed and more liver tissue can be 
obtained for detailed molecular studies than is possible in humans.  Chimpanzees could 
also play an important role in the testing of vaccine candidates.  Despite this, chimpanzee 
studies are limited due to cost and ethical considerations.  Small study numbers (usually 
2-4 animals) hamper statistical analysis and ultimate conclusions of the experiments.  As 
such new animal models are desired for further in vivo HCV research (Bukh, 2004; 
Walker, 1997; Kolykhalov et al., 1997; Bigger et al., 2001; Bukh et al., 2001b). 
1.3.3.2 Chimeric mice 
 One of the most innovative animal models for HCV research was developed in 
2001 by Mercer et al.  Mice with Severe Combined Immunodeficiency (SCID) were 
engineered to contain a plasminogen activator transgene.  These mice then had human 
hepatocytes injected into their livers.  The human hepatocytes were successfully 
transplanted into the mouse liver.  These mice can then be infected with HCV-positive 
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human serum and support viral replication in the transplanted human hepatocytes (Mercer 
et al., 2001).  Although these mice cannot be used for most work related to the immune 
response, they have been used to examine the pathogenesis of HCV and as a model for 
various HCV antiviral compound trials  (Hsu et al., 2003; Kneteman et al., 2009; Joyce et 
al., 2009; Inoue et al., 2007; Walters et al., 2006). 
1.3.3.3 Other animal models 
Another commonly used model for HCV research is transgenic mice.  Transgenic 
mice that express single HCV proteins, or a combination of HCV proteins, have been 
developed.  These mice have been used to show pathogenesis associated with expression 
of the HCV proteins (Koike et al., 1995; Pasquinelli et al., 1997; Kawamura et al., 1997; 
Wakita et al., 1998).  For example, Moriya et al. demonstrated that HCV Core expressing 
mice developed both steatosis and hepatocellular carcinoma (Moriya et al., 1997; Moriya 
et al., 1998). Transgenic mice can provide a lot of information on HCV pathogenesis, but 
they cannot be used for virus life cycle studies or in clinical trials for HCV vaccines or 
antivirals, and as such their use is limited. 
Another proposed animal model for HCV is the use of GB Virus B (GBV-B) as a 
surrogate model in tamarins.  GBV-B is the most closely related virus to HCV and it is 
only known to infect tamarins, marmosets, and owl monkeys.  However, GBV-V is most 
commonly associated with acute infection and rarely results in chronic infection.  Despite 
this, further research will be needed to determine if chimeric HCV/GBV-B viruses could 
be made that could infect tamarins and establish a chronic infection similar to HCV in 
humans.  This model could be more effectively used for antiviral and vaccine studies  
(Muerhoff et al., 1995; Bukh et al., 2001a; Warter et al., 2009; Akari et al., 2009). 
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1.4 INFLUENCE OF HCV ON LIPID METABOLISM 
1.4.1 Clinical evidence 
1.4.1.1 Blood lipid and cholesterol  
 A well-known feature of chronic HCV is the presence of hypolipoproteinemia.  
Decreased apolipoprotein B serum levels in chronic HCV patients are correlated with the 
degree of steatosis and fibrosis.  Genotype 3a infection in particular is associated with a 
more pronounced hypobetalipoproteinemia than other genotypes.  Following successful 
treatment and eradication of the virus, genotype 3a infected patients exhibit normal 
lipoprotein levels, while other genotypes do not (Moriya et al., 2003; Petit et al., 2003; 
Siagris et al., 2006).  Furthermore, chronic HCV infection is also associated with low 
serum cholesterol levels.  Hypocholesterolaemia is increased in genotype 3a infected 
patients and unlike other genotypes, it can be reversed following successful response to 
therapy (Fernandez-Rodriguez et al., 2006; Siagris et al., 2006). This suggests that the 
genotype 3a virus may cause hypolipoproteinemia and hypocholesterolaemia directly by 
using a different mechanism than other genotypes.  Further study has also revealed a 
correlation between high cholesterol and low-density lipoprotein levels in the serum and 
successful response to therapy, thereby underlining the importance of dyslipidemia in 
HCV infection (Gopal et al., 2006; Akuta et al., 2007).  In contrast, a recent study has 
examined the potential of statins in the treatment of HCV.  Statins are used in the 
treatment of hypercholersterolaemia by inhibiting 3-hydroxy-3-methyl-glutaryl-CoA 
reductase (HMG-CoA reductase).  In vitro testing revealed a decreased HCV replication 
level in the presence of flavustatin, atorvastatin, and simvastatin.  Subsequent work with 
HCV infected patients showed decreased viral load upon treatment with flavustatin and 
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strongly suggests that it could be beneficial if added to standard interferon therapy.  In 
contrast, atorvastatin appeared to have no effect (Akuta et al., 2007; Bader et al., 2008).  
1.4.1.2 Obesity 
 Recent evidence suggests that obesity may play an important role in treatment 
response and progression of disease in chronic HCV patients.  Obesity has been found to 
be a risk factor for the development of steatosis and fibrosis in chronic HCV (Hu et al., 
2004).  In addition, patients with a high body mass index have a lower chance of 
successfully responding to therapy (Bressler et al., 2003). 
1.4.1.3 Insulin resistance 
 Insulin plays a vital role in lipid metabolism, especially lipogenesis.  Type II 
diabetes is a common problem in chronic HCV patients (Mehta et al., 2000; Allison et al., 
1994).  Insulin resistance is a precursor to the development of Type II diabetes and 
insulin resistance can increase the rate of progression to fibrosis in chronic HCV (Hui et 
al., 2003). Insulin resistance occurs when higher than normal insulin concentrations are 
needed to maintain a balance of metabolic responses, such as gluconeogenesis and 
lipogenesis.  Homeostasis model assessment of insulin resistance (HOMA-IR) is used as 
a method of assessing insulin resistance.  Patients with chronic HCV consistently have a 
higher HOMA-IR level than healthy controls; however genotype 3 infected patients have 
a lower HOMA-IR than other genotypes.  Successful eradication of HCV also causes a 
decrease in HOMA-IR  (Hui et al., 2003; Bugianesi et al., 2006; Romero-Gomez, 2006a). 
Insulin resistance is closely associated with the development of steatosis.  It is believed 
that increased insulin causes increased lipogenesis in the liver; alternatively, the 
accumulation of fat in the liver may cause insulin resistance to develop (Adams and 
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Angulo, 2005; Romero-Gomez, 2006b).  In addition, chronic HCV patients have high 
Tumor Necrosis Factor Alpha (TNFα) levels.  TNFα is known to induce insulin 
resistance by interfering with insulin receptor substrates 1 and 2 signalling (Svegliati-
Baroni et al., 1999; Aytug et al., 2003). 
1.4.1.4 Steatosis 
 Steatosis, or fatty liver disease, is present in approximately 40-86% of chronic 
HCV patients of all genotypes.  Only 20-30% of the uninfected population has steatosis, 
indicating that HCV may directly or indirectly cause the accumulation of fat in the liver 
resulting in steatosis.  Steatosis is usually caused by obesity, diabetes or alcoholism and it 
can be a precursor for more severe liver disease such as non-alcoholic steatohepatitis 
(NASH), fibrosis and cirrhosis.  The prevalence of steatosis in chronic HCV is also 
higher than other liver diseases, suggesting that liver damage during infection is not the 
only reason for this association  (Mihm et al., 1997; Rubbia-Brandt et al., 2000).  In 
chronic HCV, macrovesicular steatosis is observed in the periportal region of the liver 
whereas in non-alcoholic steatosis in uninfected individuals steatosis is observed in the 
centrilobular region of the liver, suggesting that HCV induced steatosis may occur via a 
different mechanism (El-Zayadi, 2008).  
 The prevalence and degree of steatosis severity is significantly increased in people 
with genotype 3 infection (Rubbia-Brandt et al., 2000).  When patients with genotype 3 
successfully eradicate the virus after therapy, steatosis is often reversed.  This effect is 
generally not observed in non-genotype 3 patients and they often have steatosis in 
conjunction with other factors such as diabetes and obesity.  Steatosis is often observed in 
genotype 3 patients who are not obese  (Patton et al., 2004; Poynard et al., 2003; Kumar 
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et al., 2002).  This information suggests that, although all HCV genotypes contribute to 
the development of steatosis during chronic HCV, genotype 3 appears to have a different 
mechanism that may be cytopathic to hepatocytes. 
1.4.2 Molecular evidence 
1.4.2.1 Mechanisms of steatosis 
 Non-alcoholic fatty liver disease (NAFLD) is an obesity-related disorder that is 
characterized by the presence of steatosis.  Steatosis accompanied by fibrosis and cell 
death is referred to as NASH.  The mechanisms responsible for development of NAFLD, 
and specifically steatosis, are not clearly understood but are mainly associated with 
increased fatty acid uptake by the liver as well as de novo lipogenesis (Greenfield et al., 
2008).  
Steatosis is characterized by the accumulation of trigylcerides in liver cells.  
Triglycerides are neutral lipids that are composed of a glycerol backbone with three long 
chain fatty acids.  Normally triglycerides are exported for storage in adipocytes, but in 
steatosis, triglycerides remain in hepatocytes for long periods of time and can promote 
progression to NASH, fibrosis and cirrhosis.  Free Fatty Acids (FFAs) that make up 
triglycerides are usually obtained from the diet or from lipolysis of triglyceride stores in 
adipocytes.  During insulin resistance, a common contributing factor to the development 
of steatosis, increased lipolysis of triglycerides in adipocytes occurs, providing increased 
FFAs for delivery to the liver.  In addition, insulin resistance induces hyperinsulinemia 
that increases insulin binding and signaling in hepatocytes.  Increased insulin induces 
SREBP-1c activity and, subsequently, the increased expression of genes related to fatty 
acid synthesis, such as FAS (Blasiole et al., 2007). 
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1.4.2.2 Lipid droplet association and triglyceride accumulation 
 One of the first indications that HCV could alter lipid metabolism was the 
discovery that the core protein localized to lipid droplets in vitro in transfected cell 
cultures and in vivo in chimpanzees infected with HCV (Barba et al., 1997). Lipid 
droplets are pockets of neutral lipid surrounded by a phospholipid membrane and are 
present in almost every type of cell.  The functions of lipid droplets include lipid storage, 
metabolism and trafficking, membrane biogenesis, and possibly cell signaling and protein 
degradation (Fujimoto et al., 2008).  HCV core protein was also found to co-localize with 
Apolipoprotein AII, a protein commonly associated with lipid droplets  (Barba et al., 
1997; Sabile et al., 1999).  Analysis of the core protein revealed a unique, central, 
hydrophobic domain II that could play a role in lipid droplet association (Hope and 
McLauchlan, 2000).  Further mutagenesis of the domain II region and comparison with 
the GBV-B capsid protein, that also localizes to lipid droplets, revealed two regions of 
the protein that were similar to lipid droplet localizing plant oleosin proteins.  These 
sequences consisted of two proline residues at amino acid position 138 and 143, as well 
as a YATG sequence motif at amino acid location 164-167.  Deletion or mutation of 
these sequences abolished lipid droplet localization  (Hope et al., 2002).  Comparison of 
different genotypes of the core protein, specifically genotype 3, showed that genotype 3 
core localizes to lipid droplets as well and that the YATG sequence (FATG in 3a core) 
may play a role in lipid metabolism differences in genotype 3 infection (see Chapter 3) 
(Hourioux et al., 2007; Jackel-Cram et al., 2007).  The presence of the core protein also 
induces larger lipid droplets to form in cells; in particular genotype 3a core proteins that 
are associated with steatosis can induce larger lipid droplet accumulation than core 
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proteins that are not associated with steatosis in chronic HCV patients (Piodi et al., 2008; 
Abid et al., 2005).  Specific sequences of the 3a core protein have also been identified as 
being involved in steatosis and lipid accumulation in cells in cell culture (Jhaveri et al., 
2008). 
Profiling of the protein composition of lipid droplets in core-expressing cells 
revealed differences in lipid droplet composition that may indicate a role for core protein 
in lipid droplet biogenesis as well as RNA metabolism on lipid droplets (Sato et al., 
2006). Core protein was found to be able to redistribute lipid droplets in cells by lowering 
adipocyte differentiation related protein (ADRP).  This redistribution is dependent on 
microtubule networks and blockage of this process decreased viral production, indicating 
a possible role for these networks in viral assembly or release (Boulant et al., 2008). 
Localization of the core protein on lipid droplets has also been found to be 
essential for infectious virus production.  When the core protein is mutated to prevent 
lipid droplet localization, significantly decreased levels of infectious virus are produced 
in the JFH-1 cell culture system (Boulant et al., 2007).  The core protein was also found 
to recruit HCV non-structural proteins and HCV replication complexes to the surface of 
lipid droplets.  This recruitment process is essential for virus production, indicating that 
assembly of virus particles may take place close to or on lipid droplet surfaces  (Miyanari 
et al., 2007).  Indeed, further study showed that HCV assembly occurs on membranes 
adjacent to lipid droplets but not actually on lipid droplet membranes (Roingeard et al., 
2008). 
Taken together, these studies reveal the emerging importance for the lipid droplet 
in the HCV life cycle.  Core protein localization with lipid droplets in particular plays a 
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very important part in this process and may also serve to explain some of the alterations 
in lipid metabolism observed during HCV infection. 
1.4.2.3 VLDL secretion 
 It is well known that HCV associates with very low-density lipoproteins (VLDL) 
and low-density lipoproteins (LDL) in infected patients (Prince et al., 1996; Andre et al., 
2002).  This association may be very beneficial for the virus as it allows for some degree 
of immune escape and entry into cells via different host receptors (Maillard et al., 2006). 
The association of HCV with VLDL appears to occur by binding to sequences in the E1 
and E2 proteins of the virus (Monazahian et al., 2000).  Indeed, it appears as though HCV 
uses the VLDL/LDL assembly and secretion pathway for its own assembly and secretion.  
Membrane vesicles with replicating HCV contain ApoB, ApoE and Microsomal Transfer 
Protein, all of which are vital components of VLDL secretion.  Assembly of HCV occurs 
in ER and post-ER compartments.  Subsequent inhibition of VLDL assembly reduces 
HCV production and immature particles are degraded via the proteasomal pathway  
(Huang et al., 2007b; Gastaminza et al., 2008).  Several studies have suggested that novel 
inhibitors of the VLDL pathway could be used as a potential treatment for HCV. These 
include a grapefruit flavanoid naringenin and an inhibitor of long chain acyl-CoA 
synthetase 3-mediated phosphatidylcholine synthesis (Yao et al., 2008; Nahmias et al., 
2008).  HCV core protein is known to inhibit MTP activity and decrease VLDL secretion 
by itself, suggesting that it may be a key mediator of the VLDL pathway during infection 
(Perlemeuter et al., 2002).   
Levels of LDL in patient serum can also be an indicator of potential response to 
therapy (Akuta et al., 2007; Gopal et al., 2006).  Genetic polymorphisms in the ApoB 
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promoter region can indicate enhanced or decreased viral susceptibility  (Zhu et al., 
2009).  Polymorphisms in the MTP gene region are known to cause genotype 3 infected 
patients to have increased fat accumulation in their liver, indicating potential host 
involvement in the development of steatosis in genotype 3 infected individuals.  
(Zampino et al., 2008)  These results suggest a very important role for VLDL assembly 
and secretion in the assembly and secretion of HCV that could provide novel therapeutic 
targets and partially explain the association of HCV infection with the development of 
steatosis. 
1.4.2.4 Insulin resistance 
 Knowledge of the molecular mechanisms of how HCV can cause insulin 
resistance is incomplete.  Aytug et al in 2003 was able to show that Insulin Receptor 
Substrate-1 (IRS-1) and PI3K signaling was impaired in chronic HCV liver biopsy 
samples  (Aytug et al., 2003).  Further research revealed that both IRS-1 and IRS-2 were 
down-regulated by HCV due to an up-regulation of Suppressor of Cytokine Signalling-3 
(SOCS3).  Non-response to therapy could also be correlated with an up-regulation of 
SOCS3 (Kawaguchi et al., 2004; Walsh et al., 2006). The core protein is primarily 
responsible for the effect on IRS signaling.  Both genotype 1b and 3a core can down-
regulate IRS-1, but use different mechanisms.  Genotype 3a core down-regulates IRS-1 
via PPAR gamma activation and up-regulation of SOCS7 whereas genotype 1b core 
activates mammalian target of rapamycin (mTOR) to cause the down-regulation of IRS-1 
(Pazienza et al., 2007).  Core protein is also able to increase serine phosphorylation of 
IRS-1 and impair Akt/PKB signaling, thereby causing decreased glucose uptake by 
hepatocytes (Banerjee et al., 2008).  Transgenic mice expressing core protein also have 
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impaired ability to lower plasma glucose levels upon insulin stimulation and proteasome 
activator PA28 gamma is essential for the development of insulin resistance in these mice   
(Miyamoto et al., 2007). 
1.4.2.5 Oxidative stress 
 Oxidative stress occurs when the body cannot remove or repair the damage 
caused by reactive oxygen species.  Many diseases cause oxidative stress that results in 
some or all of the disease pathogenesis.  HCV has long been known to cause oxidative 
stress and it may contribute to the pathogenesis of the disease, especially liver damage 
and hepatocellular carcinoma. 
 Early research showed increased Mn-superoxide dismutase production, which 
protects cells from oxidative stress, in the PBMCs of chronic HCV patients but not in the 
liver  (Larrea et al., 1998).  Reduced glutathione was also found in erythrocytes, 
suggesting oxidative stress was occurring in HCV patients (Swietek and Juszczyk, 1997).  
Thioredoxin, which is made in response to oxidative stress, is increased in the serum of 
chronic HCV patients and correlates with the degree of liver fibrosis and non-response to 
therapy  (Sumida et al., 2000).  Cells expressing the HCV replicon showed increased 
oxidative stress during HCV replication via the p38 MAPK and JNK signaling pathways 
(Qadri et al., 2004).  Replicon cells also showed down-regulated gastrointestinal 
glutathione peroxidase that caused the cells to be more susceptible to oxidative stress   
(Morbitzer and Herget, 2005).  Increased activation of STAT3 was also observed in 
replicon cells due to oxidative stress (Waris and Siddiqui, 2005).  Core protein and the 
non-structural proteins appear to induce different antioxidant defense mechanisms 
(Abdalla et al., 2005; Garcia-Mediavilla et al., 2005).  Core protein specifically can 
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induce reactive oxygen species production, lipid peroxidation products, and antioxidant 
gene expression by causing mitochondrial injury (Okuda et al., 2002). Core protein is 
known to associate with mitochondria and inhibit electron transport, thereby causing an 
increase in ROS production (Korenaga et al., 2005). Transgenic mice expressing the core 
protein often develop hepatocellular carcinoma and an altered oxidant/antioxidant state in 
the livers of these mice, in the absence of inflammation, was thought to contribute to this  
(Moriya et al., 2001).  Induction of oxidative stress by the core protein can also cause 
activation of the PI3K/Akt pathway that subsequently increases cleavage and activation 
of SREBP to influence lipid metabolism (Waris et al., 2007).   
 High levels of oxidative stress during HCV infection can also impair interferon 
signaling and predict non-response to therapy (Di Bona et al., 2006).  Levels of oxidative 
stress are also correlated with insulin resistance  (Mitsuyoshi et al., 2008).  Furthermore, 
in non-genotype 3 patients, oxidative stress and insulin resistance appear to contribute to 
the development of steatosis.  Oxidative stress appears to play an important role in the 
pathogenesis of HCV and may also be involved in the alteration of lipid metabolism by 
HCV, but further research is needed to confirm this. 
1.4.2.6 SREBP transcription factors 
 Sterol Response Element Binding Proteins (SREBPs) are key regulators of fatty 
acid synthesis in liver cells.  SREBP-1a, SREBP-1c and SREBP-2 are members of the 
helix loop helix basic leucine zipper protein transcription factors that are controlled by 
lipid levels in hepatocytes.  SREBPs are first made as a precursor protein that is attached 
to the endoplasmic reticulum membrane.  At low lipid levels, SREBP is transported from 
the ER to the Golgi by SREBP Cleavage Activating Protein (SCAP) where it is processed 
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into the mature, nuclear form of SREBP and transported into the nucleus by Importin-β.  
Nuclear SREBP can then activate the transcription of genes containing an SRE binding 
element, such as Fatty Acid Synthase and Low Density Lipoprotein Receptor.  Nuclear 
SREBP is very unstable and is quickly phosphorylated and ubiquitinated.  Conversely, 
during high cellular lipid concentrations, Insig-1 and Insig-2 hold SCAP and the SCAP-
SREBP complex remains on the ER membrane and does not get moved to the Golgi for 
processing.  SREBP-1c is also regulated by insulin by increasing activity of PI3K/Akt 
and inducing changes in abundance of Insig-1 and Insig-2.  Insulin causes increased 
transcription of SREBP-1c as well as increased proteolytic processing (Ribaux and 
Iynedjian, 2003; Yabe et al., 2003). Activation of SREBPs has been proposed as a direct 
or indirect mechanism leading to the development of steatosis (Horton et al., 2003; 
Shimomura et al., 1999). 
 The first evidence linking HCV to the activation of SREBP was discovered using 
microarray analysis of HCV infected chimpanzee livers.  Several genes that are induced 
by SREBP were up-regulated in the chimpanzee livers, including FAS, ATP citrate lyase 
and Lipase A.  Further analysis using replicon cell lines confirmed that inhibition of the 
fatty acid synthesis pathway using cerulenin and 25-hydroxycholesterol decreased HCV 
replication, suggesting that this pathway is important in the virus life cycle (Su et al., 
2002).  In addition, SREBP-2 regulates the transcription of genes involved in cholesterol 
biosynthesis including those responsible for the production of mevalonate, a critical 
precursor involved in lipid anchoring (Sakura et al., 2001).  Inhibition of the mevalonate 
pathway by lovastatin can disrupt the HCV replication complex and inhibit HCV 
replication (Ye et al., 2003).  A geranylgeranylated protein involved in mevalonate 
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synthesis, FBL2 is able to bind NS5a and is essential for HCV replication (Wang et al., 
2005).  Up-regulation of FAS was also observed in the presence of the core protein by 
our laboratory (see Chapter 3) and this effect was mediated by SREBP-1 (Jackel-Cram et 
al., 2007).  Transgenic mice expressing core protein also have up-regulated FAS and 
SREBP-1 promoter activity; this activity is dependant on the presence of PA28 gamma.  
Microarray analysis of core transgenic mice with steatosis also revealed increased activity 
of the SREBP pathway (Moriishi et al., 2007; Chang et al., 2008).  HCV core was also 
demonstrated to increase proteolytic cleavage and phosphorylation of SREBP-1 and -2 
during cell culture infection with HCV.  This effect was caused by increased oxidative 
stress and activation of the PI3K/Akt signaling pathway (Waris et al., 2007).  Inhibition 
of FAS activity was also shown to significantly decrease HCV production in cell culture, 
suggesting this pathway may be a novel therapeutic target (Yang et al., 2008). 
Core protein is not the only protein involved in activating the SREBP pathway.  
Our results showed that NS2 is also capable of inducing transcription of FAS and 
SREBP-1 (see Chapter 5) (Oem et al., 2008). NS4b has also been shown to increase 
transcription of SREBPs as well as protein levels of SREBP and FAS via increased 
PI3K/Akt activity.  NS4b was also able to induce lipid accumulation (Park et al., 2009).  
1.4.2.7 Akt 
Akt/ PKB is a critical regulator of cellular signaling.  It plays a major role in cell 
survival, proliferation, growth and metabolism.  Akt is a serine/threonine protein kinase 
that is part of the cAMP-dependent protein kinase A/G/C family of kinases.  These 
kinases are important in cancer and diabetes and share similar mechanisms of activation 
as well as similar structures in their catalytic domain.  Three isoforms of Akt exist:  
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Akt1/PKBα, Akt2/PKBβ and Akt3/PKBγ.  All isoforms have an amino terminal 
pleckstrin homology (PH) domain, a central kinase domain and a hydrophobic motif on 
the carboxy domain.  The PH domain interacts with phosphatidylinositol (3,4,5) 
triphosphate (PIP3) that is a product of phosphatidylinositol 3 kinase (PI3K) activation.  
The central kinase domain of Akt contains a conserved Threonine residue (Thr308) 
which can be phosphorylated and partially regulate Akt activity.  The carboxy terminal 
contains the hydrophobic motif F-X-X-F/Y-S/T-Y/F that is critical for Akt activation 
through phosphorylation of the Serine or Threonine residues (Song et al., 2005; Manning 
and Cantley, 2007). 
Activation of Akt is mediated by growth factor signaling of receptor tyrosine 
kinases.  These kinases activate PI3K that phosphorylates PIP2 to form PIP3 (which can 
be reversed by PTEN).  PIP3 recruits Akt and phosphoinositide-dependent kinase-1 
(PDK1) to the plasma membrane.  Upon Akt binding PIP3 on its PH domain, the 
conformation of Akt is changed.  This allows PDK1 to phosphorylate Thr308 and mTOR 
complex 2 phosphorylates Ser473.  These residues are in slightly different positions in 
Akt2 and Akt3.  In addition, several reports have shown phosphorylation of tyrosine 
residues Tyr315, Tyr326 and Tyr474 are necessary for fully activating Akt. Other 
research has suggested PI3K independent mechanisms of Akt activation that include 
activation through PKA, Ca2+/calmodulin-dependent kinase or cellular stress and heat 
shock.  Proteins can bind to Akt and regulate its activity (Song et al., 2005; Manning and 
Cantley, 2007). 
Akt also plays a major role in the regulation of cellular metabolism.  Akt can 
phosphorylate and inhibit glycogen synthase kinase 3 Beta (GSK3β) in the presence of 
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high levels of insulin.  Once GSK3β is inhibited, glucose is metabolized and stored as 
glycogen.  Interestingly, inhibition of GSK3β may also prevent apoptosis, suggesting that 
the role of Akt in cell survival and metabolism may be connected (Manning and Cantley, 
2007). GSK3β is able to promote degradation of SREBPs.  Through inhibition of 
GSK3β, Akt is able to stabilize SREBPs and enhance lipid production in hepatic cells 
(Du et al., 2006; Porstmann et al., 2005; Fleischmann and Iynedjian, 2000; Matsumoto et 
al., 2002; Ono et al., 2003; Taniguchi et al., 2006). 
 The effect of HCV on Akt and the PI3K signaling pathway varies depending on 
the study and the protein involved.  NS5a can interact with Grb2 to activate PI3K/Akt; it 
can also bind to the p85 subunit of PI3K to activate Akt (He et al., 2002; Street et al., 
2004). The effect of NS5a on PI3K/Akt leads to the phosphorylation and deactivation of 
GSK3β.   Core protein has been shown to both impair and activate PI3K/Akt signaling.  
In T cells, core can bind to gC1qR and result in impairment of Akt phosphorylation (Yao 
et al., 2004).  Core also impaired IRS-1 and PI3K/Akt phosphorylation in the presence of 
insulin (Kawaguchi et al., 2004).  Stimulation with insulin in transgenic mice expressing 
core also resulted in decreased Akt phosphorylation  (Miyamoto et al., 2007).  Despite 
these results, core was shown to increase PI3K/Akt phosphorylation in HCV cell culture 
systems in two separate studies (Waris et al., 2007; Banerjee et al., 2008).  Replicon 
expressing cells were also able to activate PI3K/Akt by increasing production of nRas.  
Inhibition of nRas production or inhibition of Akt phosphorylation resulted in decreased 
HCV replication (Mannova and Beretta, 2005).  NS4b was also able to activate PI3K/Akt 
by itself (Park et al., 2009). 
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 These results suggest that the effect of HCV on PI3K/Akt is complex and may 
depend on the model system used as well as the cell type and the cell culture conditions 
employed.  Nevertheless, the PI3K/Akt pathway appears to play an important role in 
HCV pathogenesis. 
 
 
 
 
2.0 HYPOTHESIS AND OBJECTIVES 
 Evidence in the literature supports a strong correlation between infection with 
HCV and the development of steatosis, even in the absence of factors such as diabetes, 
obesity and alcoholism. However, clinical evidence had revealed that genotype 3a virus 
has a stronger association with the development of steatosis.  Research had focused 
primarily on the genotype 1b virus and the role of the core and NS5a proteins in lipid 
metabolism pathways.   The mechanisms for the development of steatosis during HCV 
infection were still unclear and very little research had examined the effect of genotype 
3a virus on lipid metabolism. 
 
As such, I hypothesized that: 
1.  HCV alters lipid metabolism pathways in infected hepatocytes resulting in 
increased lipid levels and the development of steatosis.   
2.  Genotype 3a virus has a stronger or differential effect on lipid metabolism 
pathways in comparison to genotype 1b virus. 
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3.  Core proteins mediate the effect on lipid metabolism but other HCV proteins 
may also have an effect. 
 
 
My objectives were: 
1.  (a) To clone and express the genotype 3a core protein in Huh-7 cells and compare 
its effect on lipid metabolism to genotype 1b core. 
(b) To examine the effect of the genotype 1b and 3a core proteins on Fatty Acid 
Synthase, a key enzyme involved in the production of triglycerides in hepatocytes. 
 
2.  To examine the effect of the genotype 1b and 3a core proteins on Sterol Response 
Element Binding Protein-1, a transcription factor that controls the expression of 
many different genes involved in lipid metabolism in hepatocytes and determine the 
mechanisms of this effect. 
 
3.  To examine the effects of other HCV proteins on FAS and SREBP-1. 
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3.1 Abstract 
Hepatitis C virus genotype-3a (HCV-3a) is directly linked to steatosis 
development.  We studied the effects of HCV-3a core protein on the promoter activity of 
fatty acid synthase (FAS), a major enzyme involved in de novo lipid synthesis. 
HCV-3a and -1b core genes were cloned and expressed.  Using a FAS promoter-
luciferase reporter, we demonstrated that both HCV-3a and -1b core proteins up-
regulated the FAS promoter.  However, HCV-3a core protein expression induced 
significantly higher FAS promoter activity than HCV-1b core.  We further showed that 
FAS up-regulation by HCV core was dependent on transcription factor sterol response 
element binding protein-1.  Mutational analysis showed that processing of HCV core 
protein of different genotypes was differentially involved in FAS promoter up-regulation.  
Although lipid droplet localization of HCV core protein was not important for FAS up-
regulation, a specific amino acid residue (Phe164) within the FATG lipid droplet 
localization sequence of HCV-3a core protein played a major role in the stronger FAS 
activation by HCV-3a core.   
The stronger effect of HCV-3a core protein on FAS activation in comparison to 
HCV-1b core could contribute to the higher prevalence and severity of steatosis in HCV-
3a infections. 
 
 
Keywords:  Hepatitis C virus, genotype 3a, core, fatty acid synthase   
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3.2 Introduction 
Hepatitis C virus (HCV) is classified into six genotypes (Pawlotsky et al., 2003).  
HCV of different genotypes may cause different pathology.  For example, in HCV-3a 
patients, the incidence of steatosis is ∼70%, which is significantly higher than infections 
by other HCV genotypes.  Furthermore, HCV-3a patients who clear the viral infection 
after interferon therapy have reduced levels of steatosis, while patients with other 
genotypes do not (Kumar et al., 2002; Poynard et al., 2003).  Therefore, HCV-3a has 
been suggested to be a strong steatogenic factor (Kumar et al., 2002; Adinolfi et al. 2001; 
Hezode et al., 2004; Hwang et al., 2001; Rubbia-Brandt et al., 2001; Rubbia-Brandt et al., 
2000; Sharma et al., 2004).  
HCV is a positive-sense RNA virus encoding a single polyprotein, which is 
cleaved by host and virus-encoded proteases to generate structural and non-structural 
proteins (Poynard et al., 2003; Choo et al., 1991).  Core protein is a structural protein, but 
it also modulates host cellular pathways, including those involved in lipid metabolism 
(Ray et al., 2001).  The core protein exists in immature and mature forms.  After cleavage 
from the polyprotein, the immature form is further processed by an endoplasmic 
reticulum membrane-associated signal peptide peptidase around amino acid residues 173 
to 186 to generate the mature core protein (Ray et al., 2001; Kato et al., 2003; Liu et al., 
1997; Lemberg et al., 2002). 
HCV core protein localizes on lipid droplets (Barba et al., 1997; Shi et al., 2002; 
Rouille et al., 2006; Perlemuter et al., 2002), suggesting a potentially functional role in 
lipid metabolism.  HCV-1 core protein has been shown to modulate the activity of 
microsomal triglyceride transfer protein, RXRalpha, and peroxisome proliferators-
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activated receptor α (Perlemuter et al., 2002; Yamaguchi et al., 2005; Tsutsumi et al., 
2002; Cheng et al., 2005).  It is noteworthy that HCV-3a core induces increased amounts 
of triglyceride (TG) accumulation over the core proteins of other genotypes (Abid et al., 
2005).  Therefore, HCV core protein is actively involved in lipid metabolism and, more 
importantly, HCV-3a core may have a more profound impact than core proteins of other 
genotypes.  
Fatty acid synthase (FAS) plays a central role in de novo lipid synthesis and TG 
accumulation in hepatocytes by catalyzing the reaction of acetyl-CoA and malonyl-CoA 
into palmitate which is esterfied into TG (Semenkovich et al., 1997).  FAS expression is 
primarily regulated at the transcriptional level by sterol response element binding protein-
1 (SREBP-1) (Semenkovich et al., 1997; Shimano et al., 2001).  Alteration of the 
SREBP-1-FAS pathway can result in clinical manifestations such as steatosis and 
diabetes (Horton et al., 2002). 
In this study, we examined the effect of HCV core protein on FAS promoter 
activity.  We found that while the expression of HCV-3a and HCV-1b core proteins in 
Huh-7 cells up-regulated FAS promoter in a SREBP-1-dependent manner, the effect of 
HCV-3a core was significantly stronger than that of HCV-1b core. We further showed 
that a single amino acid residue (F164) of HCV-3a core protein was critical for this 
process.    
3.3 Materials and Methods 
 
3.3.1 Plasmid constructs 
HCV-3a infected human sera samples were used for RNA extraction by TriZol 
(Invitrogen).  RNA was then reverse transcribed into cDNA with random hexamers and 
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reverse transcriptase (SuperScript III-RT, Invitrogen).  HCV core gene was amplified 
from cDNA using core-specific primers (Forward: 5’-
aattgaattcATGAGCACACTTCCTAAACCTC-3’, EcoRI site; and Reverse: 5’- 
aatttctagattaGGCATCGACCCCTGAGAACAT-3’, XbaI site). A stop codon was 
incorporated in the reverse primer to terminate the translation.  PCR was performed using 
DeepVent DNA polymerase (New England Biolabs) (35 cycles; 94ºC 30 sec, 50ºC 30 
sec, 72ºC 1 min).  The PCR product of 573 bps in size was cloned into the pEF/cyto/myc 
vector (Invitrogen) by restriction enzymes EcoRI and XbaI.  HCV-1b core was cloned by 
a similar PCR-based approach using plasmid pDM22, a cDNA clone of HCV-BK 
(Manabe et al., 1994).  Amino acid substitutions or deletions were achieved by primer-
driven mutagenesis. All the plasmids were confirmed by DNA sequencing.   
 
3.3.2 Cell culture, transfection, and immunofluorescence 
Human hepatoma Huh-7 cells were maintained in Dulbecco’s Modified Eagle’s 
Medium (10% fetal bovine serum, 1% non-essential amino acids, 1% gentamicin) at 5% 
CO2, 37ºC.  Huh-7 cells grown in 4-well chamber slides were transfected with 1.0 µg of 
plasmid DNA using the calcium phosphate precipitation method (Graham et al., 1973).  
Forty-eight hours after transfection, cells were washed in PBS and fixed in 4% 
paraformaldehyde.  Cells were then permeabilized in 0.1% Triton X-100, washed and 
blocked with 3% BSA in PBS.  After further washing, cells were incubated with an anti-
core monoclonal antibody followed by a secondary antibody (AlexaFluor-488 goat anti-
mouse, Molecular Probes).  Cells were then rinsed in 60% isopropanol and incubated 
with Oil Red O stain (dissolve 0.5 mg/mL of oil red O in isopropanol overnight, filter and 
47 
mix 6 parts oil red O to 4 parts water just prior to staining).  Cells were rinsed twice in 
60% isopropanol and then in PBS.  DAPI (4’,6-diamidino-2-phenylindole, 300 nM in 
PBS, Molecular Probes) was added to the cells for 5 min.  After washing, the slides were 
mounted in Prolong Antifade (Molecular Probes) and allowed to dry overnight in the 
dark.  For endoplasmic reticulum (ER) staining, cells were incubated with a calnexin-
specific antibody (Santa Cruz Biotechnology) followed by a secondary antibody 
(AlexaFluor-594 goat anti-rabbit, Molecular Probes).  Images were collected using a 
confocal microscope (Zeiss LSM410) with appropriate laser settings and processed using 
Adobe-Photoshop-8.0.   
 
3.3.3 Western blot analysis  
Huh-7 cells grown in 6-well plates were transfected with 2 µg plasmid DNA.  
Cells were lysed in lysis buffer (1% SDS, 10 mM Tris-HCl pH 8.0) 48 hours after 
transfection.  Proteins separated in 15% polyacrylamide gels were transferred onto PVDF 
membranes and blocked in 2% skim milk. Membranes were incubated at 4ºC overnight 
with a core-specific monoclonal antibody or β-actin-specific polyclonal antibody (Cell 
Signaling Technology).  After washing, membranes were then incubated with HRP-
conjugated anti-mouse or anti-rabbit IgG antibody (Santa Cruz Biotechnology).  Protein 
bands visualized by the Immobilon Chemiluminescence System (Millipore) were 
subjected to densitometry analysis using the Quantity-One software (Bio-Rad).   
 
3.3.4 Luciferase Assays 
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Huh-7 cells grown in 24-well plates were co-transfected with 0.5 µg of core-
expressing plasmids, 0.5 µg of a plasmid encoding firefly luciferase under the control of 
wild-type or SRE site deleted FAS promoter (Swinnen et al., 1997), and 0.02 µg of pRL-
SV40 encoding Renilla luciferase (rLuc) (Promega).  In another series of experiments, a 
plasmid encoding a dominant negative (DN) mutant SREBP-1 protein was included in 
the co-transfection.  The DN-SREBP-1 gene (Heemers et al., 2001) was cloned into 
pcDNA3.1(+) (Invitrogen) by restriction enzymes EcoRI and SpeI.  Luciferase assay was 
performed 48 hours after transfection with Dual Luciferase Assay reagents (Promega) 
using a TD 20/20 luminometer (Turner Designs).  The luciferase readings of each sample 
were first normalized against the rLuc levels and then normalized against the 
corresponding amount of HCV core proteins. 
 
3.3.5 Statistical analysis 
All experiments were performed at least three times.  Results were analyzed for 
statistical differences using Student t test.  A p value of ≤ 0.05 was considered 
statistically significant. 
 
3.4 Results 
3.4.1 Cloning and expression of HCV-3a core 
HCV-1b and -3a core gene was cloned into the pEF/cyto/myc vector as described 
in Materials and Methods.  Amino acid sequence analysis showed that the 3a core protein 
sequence that we cloned had 98% similarity to that of a published 3a core (GenBank 
Accession No. D17763) and ∼ 90% similarity to that of 1b (BK) core protein (Fig.1a).  
49 
Western blot analysis showed that 3a core protein was expressed at a lower level than 1b 
core when they were analyzed in one protein gel, although the same amount of proteins 
was used for loading as demonstrated by equal β-actin levels (Fig. 3.1b).   
 
3.4.2 HCV-3a core protein localizes on lipid droplets in Huh-7 cells  
As previous studies have demonstrated that HCV core protein localizes on lipid 
droplets (Barba et al., 1997; Shi et al., 2002; Rouille et al., 2006), we studied subcellular 
localization of HCV-3a core protein.  Immunofluorescence experiment demonstrated that 
3a core protein was found in surrounding large circular structures, which could be stained 
with Oil Red O, an intracellular lipid droplet stain (McVean et al., 1965) (Fig. 3.1c).  In 
addition, co-staining of core and calnexin was observed, consistent with ER localization 
of HCV core protein (Fig. 3.1d).   
 
3.4.3 HCV core protein up-regulates FAS promoter in an SREBP-1 dependant 
manner 
 Since FAS is a major enzyme in lipid metabolism, we investigated whether the 
expression of HCV core proteins has any effect on FAS transcription using a FAS 
promoter-luciferase reporter containing the 178 bp fragment of the FAS proximal 
promoter (Swinnen et al., 1997).   Expression of 3a and 1b core proteins resulted in 
significantly higher luciferase activity than vector transfection (Fig. 3.2a; 3a core vs. 
control, p=0.00000006; 1b core vs. control, p=0.0234).  Importantly, cells transfected by 
3a core-expressing plasmid exhibited significantly higher luciferase activity than 1b core 
transfection (Fig. 3.2a, 3a core vs. 1b core, p=0.000002). 
50 
 Since SREBP-1 is the major transcriptional factor for modulating FAS 
transcription by binding to the SRE site on the FAS promoter (Shimano et al., 2001), we 
studied the role of SREBP-1 in HCV core-induced FAS promoter up-regulation.  For this 
purpose, a FAS promoter-luciferase reporter with the SREBP binding site deleted (from -
63 to -46) (ΔSRE) was utilized.  After transfection of the FAS-ΔSRE promoter reporter, 
luciferase activity was barely detectable (Fig. 3.2a), indicating that FAS up-regulation by 
HCV core was mediated through SREBP-1.  Interestingly, the basal FAS promoter level 
was also suppressed after transfection of the FAS-ΔSRE promoter reporter (Fig. 3.2a), 
suggesting that FAS activation was mediated primarily by SREBP-1 in Huh-7 cells.  
 To further confirm the involvement of SREBP-1 in FAS up-regulation by HCV 
core proteins, Huh-7 cells were transfected with a plasmid expressing DN-SREBP-1, 
together with HCV core-expressing plasmids, and the wild-type FAS promoter reporter.  
While plasmid vector transfection did not have any effect, luciferase activity was 
decreased to similar levels in DN-SREBP-1 transfected cells (Fig. 3.2b). 
 
3.4.4 Role of core protein processing in FAS up-regulation  
Previous studies have shown that amino acid residues 180, 183, and 184 are 
involved in core protein processing (McLauchlan et al., 2002; Okamoto et al., 2004).  To 
investigate the role of core protein processing in FAS up-regulation, a mutant carrying 
triple mutations (A180V, S183L, and C184V) was generated for both HCV-1b and -3a 
core (Fig. 3.3a).  Western blot analysis showed inhibition of processing of the mutant 
core proteins, although processed core was still evident (Fig. 3.3b).  Subcellular 
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localization studies of the mutant core proteins showed a reduced lipid droplet 
localization of both 1b and 3a core mutants (Fig.3.3c).   
The processing mutants of HCV core were then used to measure FAS promoter 
activity.  FAS promoter activity after expression of 1b coreASC/VLV mutant was not 
statistically different from 1b coreWT (Fig. 3.3d, 1b coreWT vs. coreASC/VLV, p=0.5).  In 
contrast, expression of 3a coreASC/VLV resulted in significantly higher FAS promoter 
activity than coreWT (Fig. 3.3e, 3a coreWT vs. coreASC/VLV, p=0.000014).  These results 
suggest that partial alteration in HCV-3a core protein processing had a measurable effect 
on FAS promoter up-regulation. 
 Since deletion of 18 amino acid residues from the C-terminus represents the fully 
processed form of HCV core protein (Liu et al., 1997; Yamanaka et al., 2002),  we 
generated the truncated forms of the core proteins of both genotypes and studied their 
role in FAS up-regulation.  Both 1b and 3a core proteins were truncated till amino acid 
173 from the C-termini.  Western blot analysis showed the presence of the core protein at 
a size consistent with the processed core protein (tCore173 in Fig. 3.3b).  When the 
subcellular localization of the truncated core proteins was examined, a dramatic 
difference was observed (Fig. 3.3c).  The 1b tCore173 protein localized primarily in the 
cytoplasm.  A small number of cells (~15%) exhibited lipid droplet localization.  In 
contrast, 3a tCore173 protein was primarily localized in the nucleus.  No lipid droplet 
localization was observed.   
When the truncated core proteins were used for measuring FAS promoter activity, 
expression of HCV-1b tCore173 was associated with significantly higher FAS promoter 
activity (Fig. 3.3d, 1b coreWT vs. 1b core173, p=0.00009).  In contrast, 3a tCore173 was no 
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longer able to up-regulate FAS promoter (Fig. 3.3e, 3a tCore173 vs. control, p=0.5).  
These results suggested that fully processed and nuclear HCV-3a core protein did not up-
regulate FAS promoter.   
 
3.4.5 Role of lipid droplet localization in FAS up-regulation by HCV core protein  
Previous studies have identified that 164YATG167 sequence of 1b core protein is 
crucial for lipid droplet localization (Hope et al., 2000; Hope et al., 2002).  HCV-3a core 
encodes a phenylalanine instead of a tyrosine at position 164 (Fig. 3.1a).  To study the 
effect of 164YATG167 or 164FATG167 sequences in FAS activation, this sequence was 
deleted from 1b or 3a core and the expression of the mutant proteins was confirmed by 
Western blotting (Fig. 3.4a and 3.4b).  Immunofluorescence analysis revealed a decrease 
in the overall amount of core protein localizing to lipid droplets (Fig. 3.4c).  These results 
did not only confirm the role of the 164YATG167 motif in lipid droplet localization for 1b 
core protein, but also demonstrated that the 164FATG167 motif was involved in directing 
HCV-3a core protein onto lipid droplets.  When these mutants were used to determine 
FAS promoter activity, deletion of the 164YATG167 or 164FATG167 sequences in 1b or 3a 
core entirely abolished FAS promoter activation (Fig. 3.4d and 3.4e; control vs. 1b 
coreΔYATG, p=0.45, control vs. 3a coreΔFATG, p=0.54).  
 A proline knot motif (composed of two proline residues within the sequence 
138PLVGAP143) of the 1b core protein is also critical for lipid droplet localization (Hope 
et al., 2002).  The proline knot motif is conserved in HCV-3a core protein (Fig. 3.1a).  To 
characterize the role of the proline knot motif in FAS activation, the two proline residues 
were changed to alanines (Fig. 3.4a).  Western blot analysis demonstrated the expression 
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of the mutant coreP138A/P143A proteins (Fig. 3.4b).  Subcellular localization of the proline 
knot mutants showed a significant decrease in lipid droplet localization for both 
genotypes (Fig. 3.4c).  When examined for FAS promoter analysis, expression of 1b and 
3a coreP138A/P143A mutants resulted in significantly higher FAS promoter compared to 
coreWT (Fig. 3.4d, 1b coreWT vs. 1b coreP138A/P143A, p=0.0002; Fig. 3.4e, 3a coreWT vs. 3a 
coreP138A/P143A, p=0.00003).  These results suggest that the two lipid droplet localization 
motifs in HCV core protein had different effects on FAS promoter up-regulation. 
 
3.4.6 Involvement of phenylalanine164 of HCV-3a core protein in FAS up-regulation 
To investigate the role of phenylalanine164 of 3a core in FAS up-regulation, we 
mutated the phenylalanine164 to a tyrosine, which is present in the 1b core (Fig. 3.5a).  
Western blot analysis showed similar processing and expression levels of 3a coreWT or 
coreF164Y proteins (Fig. 3.5b).  Subcellular localization of 3a coreF164Y protein was also 
very similar to the wild-type with the majority of the core protein localizing on lipid 
droplets around the nucleus (Fig. 3.5c).  The 3a coreF164Y mutant was then used to 
examine FAS promoter activity.  Expression of 3a coreF164Y was associated with 
significantly higher FAS promoter activity than control (Fig. 3.5c, control vs. 3a 
coreF164Y, p=0.0043).  However, FAS promoter activity was significantly reduced after 3a 
coreF164Y expression in comparison to 3a coreWT (Fig.5c, 3a coreWT vs. coreF164Y, 
p=0.00057).  These results indicate that phenylalanine164 of 3a core plays a major role in 
FAS promoter activation. 
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3.5 Discussion 
 Clinical investigations suggest that HCV-3a is a stronger steatogenic factor than 
HCV of other genotypes.  However, the molecular mechanisms underlying this process 
have not been well characterized.  In this study, we demonstrated that expression of 
HCV-3a core protein resulted in significantly stronger up-regulation of FAS promoter 
than 1b core.  In addition, we identified that phenylalanine164 encoded by HCV-3a core 
protein was primarily responsible for this increased effect.  
 It has been well documented that regulated proteolytic cleavage of HCV core 
protein results in the presence of processed and unprocessed core proteins (Kato et al., 
2003; Liu et al., 1997; Yamanaka et al., 2002).  The regulated core protein processing 
plays a role in determining its function (Yamanaka et al., 2002; Moorman et al., 2003; 
Bergqvist et al., 2001).  In this paper, we showed that partial prevention of processing by 
amino acid mutations at the carboxyl-terminus abolished FAS activation by HCV-1b 
core, but enhanced 3a core associated FAS activation (Fig. 3.3d and 3.3e).  In contrast, 
only fully-processed HCV-1b core, but not 3a core, could up-regulate FAS promoter (Fig. 
3.3d and 3.3e).  These results indicated that regulated processing of core proteins of 
different HCV genotypes was differentially involved in FAS promoter regulation.  The 
underlying mechanism is a subject for subsequent studies. 
Since FAS is directly linked to intracellular lipid synthesis (Semenkovich et al., 
1997; Sul et al., 1998) and lipid droplet is the major organelle for intracellular lipid 
storage (Martin et al., 2006), we investigated the role of lipid droplet localization of HCV 
core protein in FAS up-regulation.  Consistent with previous studies (Hope et al., 2000; 
Hope et al., 2002), mutations of the proline knot and the Y/FATG sequences of HCV 
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core protein resulted in reduced lipid droplet localization.  Somewhat to our surprise, the 
proline knot and Y/FATG mutations had different effects on FAS promoter activity (Fig. 
3.4).  While the expression of proline knot mutant of either 1b or 3a core proteins resulted 
in enhanced FAS promoter activity, YATG (1b) or FATG (3a) deletion totally abolished 
FAS promoter up-regulation.  These results indicated that lipid droplet localization of 
HCV core protein did not play a major role in up-regulating FAS.  Instead, the primary 
amino acid sequences, i.e., YATG (1b) and FATG (3a), were critical for FAS up-
regulation.  In addition, this short amino acid stretch might also be responsible for the 
stronger FAS activation by 3a core than 1b core.  Indeed, changing the phenylalanine to 
tyrosine in HCV-3a core protein significantly reduced the degree of FAS promoter 
activation.  This result suggested that the phenylalanine164 of 3a core was involved in 
FAS up-regulation.   
The molecular mechanism for the involvement of phenylalanine164 of 3a core 
protein in FAS activation is not known.  One possibility is that the phosphorylation status 
at this particular position of HCV core protein is important.  Although serine 
phosphorylation of HCV-1 core protein has been demonstrated (Lu et al., 2002; Shih et 
al., 1995), whether the tyrosine164 of HCV-1b core protein is phosphorylated is yet to be 
determined.  Alternatively, since HCV core interacts with numerous cellular proteins 
(Kang et al., 2005), the presence of a phenylalanine or a tyrosine at this position may 
influence these interactions, which in turn influence FAS activation.  Future research will 
clarify this issue. 
 In conclusion, our research showed a stronger activation of FAS promoter by 
HCV-3a core than 1b core.  This result increased our understanding of the mechanisms 
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by which HCV-3a infections are associated with higher prevalence and severity of 
steatosis. 
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Figure 3.1.  Expression and subcellular localization of HCV-1b and -3a core 
proteins.  A) Amino acid sequence comparison of HCV-1b and -3a core proteins.  B) 
Expression of HCV core proteins.  Huh-7 cells were transfected with pEF/cyto/myc 
vector (control), or plasmids expressing HCV-1b core or -3a core.  Core proteins were 
analyzed by Western blotting using a core-specific antibody 48 hr after transfection.  The 
levels of β-actin were blotted for protein loading control.  C) and D) Subcellular 
localization of HCV core proteins in Huh-7 cells.  After transfection, HCV core protein 
was detected with a core-specific monoclonal antibody and a secondary antibody 
conjugated with Alexa Fluor 488 (Molecular Probes).  Lipid droplets and endoplasmic 
reticulum (ER) were detected by Oil Red O (C) or a calnexin-specific antibody (D), 
respectively.  The nuclei were detected by DAPI.  Scale bar, 20 µm. 
58 
A  
 
 
B 
 
 
C 
 
 
Figure 3.1 
59 
D 
 
 
Figure 3.1 
60 
Figure 3.2.  HCV core protein up-regulates FAS promoter in Huh-7 cells in an 
SREBP-1-dependant manner.  A) Huh-7 cells were co-transfected with HCV-1b or -3a 
core-expressing plasmids, together with pGL3-basic vector, a FAS promoter-luciferase 
reporter plasmid, or an SRE-deleted FAS promoter reporter.  Plasmid pRL-SV40 
encoding Renilla luciferase was also included in the co-transfection experiment.  
Luciferase assay was carried out 48 hr after transfection.  FAS promoter activity was 
expressed as relative light units (RLU) after normalization of the firefly luciferase against 
the Renilla luciferase levels followed by normalization against the core protein levels in 
Fig. 1b.  The statistical difference between the samples was demonstrated as * if p ≤ 0.05 
or ** if p ≤ 0.01.  B) Huh-7 cells were co-transfected with HCV-1b or -3a core-
expressing plasmids, a FAS promoter-luciferase reporter plasmid, together with 
pcDNA3.1(+) vector or a plasmid expressing a dominant-negative mutant of SREBP-1.  
Luciferase assay was performed 48 hr after transfection to determine FAS promoter 
activity. 
 
 
 
 
 
 
 
 
 
61 
A 
 
B 
 
Figure 3.2
62 
Figure 3.3.  The role of HCV core proteolytic processing on FAS promoter up-
regulation.  A) HCV-1b or -3a core processing mutants were generated by amino acid 
substitutions at three positions at the carboxyl-terminus (A180V/S183L/C184V).  B) 
Expression of HCV core processing mutant proteins.  Huh-7 cells were transfected with 
pEF/cyto/myc vector (control), or plasmids expressing 1b coreASC/VLV or 3a coreASC/VLV.  
Truncations were also created by deleting the C-terminal 18 amino acids of 1b or 3a core 
proteins (core173) and used in transfection.  The expression of mutant core proteins was 
analyzed by Western blotting using a core-specific antibody 48 hr after transfection.  C) 
Subcellular localization of the processing mutant core proteins in Huh-7 cells.  HCV core 
proteins were stained with a core-specific monoclonal antibody.  Lipid droplets were 
stained by Oil Red O and the nuclei were stained by DAPI.  Scale bar, 20 µm.  D) and E) 
FAS promoter activity after expression of HCV-1b (Fig.3d) or -3a (Fig.3e) core 
processing mutants.  Huh-7 cells were co-transfected by a FAS promoter-luciferase 
reporter and pEF/cyto/myc vector (control), or plasmid expressing coreWT, or coreASC/VLV, 
or core173.  Luciferase assay was performed 48 hr after transfection to determine FAS 
promoter activity.  
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Figure 3.4.  Effect of lipid droplet localization of HCV core proteins on FAS 
promoter up-regulation.  A) Lipid droplet localization motifs in HCV core protein.  
Two prolines at positions 138 and 143 (red) representing a proline knot were mutated to 
alaines.  The 164YATG167 motif of 1b core or the 164FATG167 sequence of 3a core was 
deleted.  B) Expression of HCV core lipid droplet localization mutants determined by 
Western blotting using a core-specific antibody after transfection in Huh-7 cells.  C) 
Subcellular localization of core proteins with lipid droplet localization motif mutations.  
HCV core proteins were stained with a core-specific monoclonal antibody.  Lipid 
droplets were stained by Oil Red O and the nuclei were stained by DAPI.  Scale bar, 20 
µm.  D) and E) FAS promoter activity after expression of HCV core lipid droplet 
localization mutants in 1b core (3d) or 3a core (3e).  Huh-7 cells were co-transfected with 
a FAS promoter-luciferase reporter, together with pEF/cyto/myc vector (control), or 
plasmid expressing coreWT, or coreΔY/FATG, or coreP138A/P143A.  Luciferase assay was 
performed 48 hr after transfection.  
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Figure 3.5.  Involvement of F164 in HCV- 3a core protein in FAS promoter up-
regulation.  A) Expression of 3a coreF164Y.  Huh-7 cells were transfected with 
pEF/cyto/myc vector (control), or plasmid expressing 3a wild-type or F164Y mutant core 
proteins.  Western blot analysis was performed 48 hr after transfection using a core-
specific antibody.  B) Subcellular localization of the 3a coreF164Y mutant.  After 
transfection, the core protein was stained with a core-specific monoclonal antibody and a 
secondary antibody conjugated with Alexa Fluor 488 (Molecular Probes).  Lipid droplets 
were stained by Oil Red O and the nuclei were stained by DAPI.  Scale bar, 20 µm.  C) 
FAS promoter activity after expression of 3a coreF164Y mutant.  Huh-7 cells were co-
transfected with a FAS promoter-luciferase reporter, together with pEF/cyto/myc vector 
(control), or plasmid expressing 3a coreWT, or coreF164Y mutant.  Luciferase assay was 
performed 48 hr after transfection. 
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4.1 Abstract  
Hepatitis C virus genotype-3a (HCV-3a) is directly linked to the development of 
steatosis, or fatty liver.  Previously, we studied the effects of HCV-3a core protein on the 
promoter activity of fatty acid synthase (FAS), a major enzyme involved in de novo lipid 
synthesis that is regulated by Sterol Response Element Binding Protein-1 (SREBP-1). 
The signal transduction pathways responsible for FAS up-regulation by HCV-3a core 
protein are not understood.  In this study we further investigated the role of the HCV-3a 
core protein in altering SREBP-1 activity by examining its effect on Akt, an important 
cell signaling protein. 
Genomic replicon expressing cells were established that contain the genotype 3a core in a 
genotype 1b N strain backbone.  The chimeric genotype 3a replicon up-regulated 
transcriptional activity of SREBP-1c in an SRE and LXRE dependent manner in 
comparison to the genotype 1b replicon.  SREBP-1 processing into the mature form was 
also enhanced in genotype 3a core expressing cells.  Further examination revealed that 
Akt-1 and Akt-2 phosphorylation was increased in the presence of genotype 1b and 3a 
core proteins, with a greater effect of 3a core.  When Akt activity was inhibited using 
chemical inhibitors LY294002 or AktVIII or by using dominant negative Akt plasmids, 
the effect of 3a core protein on transcriptional activity from the SRE and SREBP-1c 
promoter activity was inhibited. Knocked down Akt-1 or Akt-2 with shRNAs had a 
similar effect.  These results indicated a role for HCV-3a core protein in regulating Akt 
activity, especially those involved in regulation of lipogenic gene expression. 
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4.2 Introduction 
  Infection with hepatitis C virus (HCV) results in the development of hepatitis, 
steatosis, fibrosis, cirrhosis, hepatocellular carcinoma and the eventual need for liver 
transplantation. Different genotypes of the virus, based on sequence homology, cause 
different clinical pathologies and also differ in their response rates to interferon/ 
Ribavirin combination therapy.  Clinical evidence has shown that genotype 3a may have 
a direct cytopathic effect on hepatocytes, with approximately 70% of patients developing 
steatosis, or fatty liver, in the absence of other contributing factors such as obesity, 
diabetes and alcoholism.  Furthermore, clearance of the genotype 3a virus decreases or 
abolishes the presence of steatosis (Castera et al., 2004). Other genotypes do not appear 
to contribute as directly to the development of steatosis.  The presence of steatosis can 
hamper successful clearance of the virus during therapy as well as increase the 
progression of the liver to cirrhosis. 
Genotype 1b core protein can enhance the processing of Sterol Response Element 
Binding Protein-1 (SREBP-1) and SREBP-2, key transcription factors that activate genes 
involved in lipid and cholesterol metabolism such as Fatty Acid Synthase (FAS) through 
binding of the Sterol Response Element in the gene promoters (Horton et al., 2002; 
Latasa et al, 2000). SREBP-1 and SREBP-2 are localized on the endoplasmic reticulum 
in a complex with SREBP Cleavage Activating Protein (SCAP) until low cholesterol 
and/or lipid levels or increased insulin induces the complex to move into the Golgi, where 
SREBP-1/2 is cleaved and the amino terminal end is released into the cytoplasm to 
localize in the nucleus and regulate transcription of lipid metabolism genes (Bengoechea-
Alonso and Ericsson, 2007; Raghow et al., 2008).  The influence of HCV core on these 
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transcription factors could play an important role in the development of steatosis during 
chronic HCV infection. 
Previous research has shown that the core protein of genotype 3a HCV may have 
a differential mechanism in regulating lipid metabolism during infection in comparison to 
genotype 1b, although the exact molecular mechanisms are not well understood (Abid et 
al., 2005; Hourioux et al., 2007; Pazienza et al., 2008; Piodi et al., 2008; Waris et al., 
2007). The core protein localizes to lipid droplets in transfected and infected Huh7 cells 
and abrogation of this localization decreases the production of infectious virus particles, 
indicating that localization of core on lipid droplets is important for virus assembly 
(Miyanari et al., 2007). Genotype 1b HCV core has been shown to influence Microsomal 
Transfer Protein (MTP) activity, which is the enzyme involved in packaging triglycerides 
into Very Low Density Lipoproteins (VLDL) for secretion, and subsequently decreases 
apolipoprotein B-100 secretion (Perlemuter et al., 2002). Transgenic mice expressing 
core protein also develop steatosis (Moriya et al., 1998). Furthermore, a recent study has 
shown that FAS protein expression is substantially increased in JFH-1 cell culture 
infection; when FAS expression was inhibited, viral production and entry were decreased 
(Yang et al., 2008). These data suggest that the influence of HCV on lipid metabolism 
may not only be important for the development of steatosis, but also for viral infection 
and therefore could be a viable drug target. 
Our previous study has shown that genotype 3a core protein is able to up-regulate 
transcription of FAS to a greater extent than genotype 1b core protein in an SREBP-1 
dependant manner (Chapter 3: Jackel-Cram et al., 2007). In this study we have further 
investigated how genotype-3a and 1b core protein influence SREBP-1 transcription and 
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processing through increasing activity of Akt-1 and Akt-2. These results provide further 
information on the important differences between genotype 1b and 3a HCV infection and 
how it may lead to the development of steatosis. 
 
4.3 Materials and Methods 
 
4.3.1 Plasmids, Antibodies and Reagents.   
A plasmid containing the SREBP-1c promoter region (-571/+90) was provided by 
Dr. Lefai (Dif et al., 2006). The promoter truncations and SRE and LXRE deletions were 
generated using site directed mutagenesis as previously described (Oem et al., 2008).  A 
plasmid containing His6-tagged Akt-2 was generated for use in His-tagged protein pull 
down for Akt-2 phosphorylation studies.  HCV core antibody was purchased from 
Anogen and NS5b antibody was obtained from Dr. Joyce Wilson.  SREBP-1 antibody 
was obtained from Santa Cruz Biotechnology. Antibodies for total Akt-1, total Akt-2, 
phospho-Ser Akt, and β-actin were purchased from Cell Signaling Technology.  
LY294002 was purchased from EMD Biosciences.  
 
4.3.2 Transfections.   
Huh7 cells were transfected using calcium phosphate precipitation as previously 
described (Jackel-Cram et al., 2007). 
 
 
 
78 
4.3.3 Generation of 1b/3a chimeric replicon.   
Huh7 cells stably expressing an HCV-1b N genomic replicon were kindly 
provided by Dr. S. Lemon. Genotype 3a core coding sequence was cloned in place of the 
1b core protein in the N replicon through PCR-mediated recombination. RNA generated 
by in vitro transcription from linearized plasmid DNA was electroporated into replicon-
cured Huh7 cells (provided by Dr. Joyce Wilson).   Cells were selected using G418 and 
the resultant colonies were examined for replicon expression using Western blots and 
RT-PCR. For transient replication assays, plasmids containing a T7 promoter and the 
HCV genomic (HCV-1b N or HCV-3a core/1b N) or subgenomic  (HCV-1b N or HCV-
1b N GND mutant) virus sequences with a luciferase reporter gene were used to generate 
RNA with an Ambion T7 megascript kit.  2.5 µg of RNA was transfected into Huh7 cells 
using DMRIE-C (Invitrogen).  Cells were lysed in Passive Lysis Buffer (Promega) and 
assayed for luciferase activity at selected time points. 
 
4.3.4 Western blot analysis and Histidine-tagged protein pull-down assay.  
All cells were cultured with Dulbecco’s Modified Eagles Medium containing 1% 
Fetal Bovine Serum for 24 hours prior to harvesting.  Cells were harvested 48 hours after 
transfection with Cell Lysis Buffer (Cell Signaling Technology) containing 10 µM 
phenylmethylsulphonyl fluoride (PMSF) according to the manufacturer’s protocol.  Total 
protein was quantified.  For His-tagged protein pull-down, equivalent amounts of cell 
lysates were added to nickel resin (Qiagen) overnight at 4 °C.  The resin was washed 4X 
in Phosphate Buffered Saline (pH 7.2) and then eluted in elution buffer.  For Western 
blotting, total protein or His-tagged pulled down proteins were subjected to SDS-PAGE, 
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blotted onto nitrocellulose, blocked in 3% Bovine Serum Albumin, and placed in primary 
antibody overnight.  Blots were washed and incubated in secondary antibody (Li-Cor) for 
one hour and then washed again.  Blots were then scanned using a Li-Cor Odyssey 
scanner at 600 nm (anti-mouse secondary) or 700 nm (anti-rabbit secondary) and 
fluorescent intensity of the resulting bands was quantified using the Odyssey software. 
 
4.3.5 Luciferase assays.   
Cells were plated at 4 x 104 per well of 24-well plates and cultured overnight.  
Cells were transfected with a maximum of 1.05 µg of plasmid including a Renilla 
Luciferase internal control.  Media was changed 24 hours after transfection to DMEM 
with 1% FBS and appropriate inhibitors were added if necessary.  Cells were washed and 
harvested in Passive Cell Lysis Buffer and luciferase activity was assayed according to 
the protocol of the Promega Dual Luciferase Assay system.  Luciferase levels were 
normalized to the level of Renilla luciferase activity and statistical significance was 
determined by a student’s t test. 
 
4.3.6 Generation of Akt-1 and Akt-2 knock out cells.  
Akt-1 or Akt-2-specific small hairpin (sh) RNA lentiviral constructs (Open 
Biosystems) were co-transfected with lentivirus packaging plasmids into HEK293T cells. 
The resulting lentiviral particles were used to infect Huh7 cells. 24 hours post-infection, 
2.5 mg/ml of puromycin was added to select for infected cells. Akt-1 or Akt-2 knock-
down was confirmed by Western blotting.  A non-silencing construct was used to 
generate control cells (Fig 4.5). 
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4.4 Results 
 
4.4.1 Generation and characterization of HCV chimeric replicon.  
In order to compare the actions of genotype 1b core to genotype 3a core protein, 
we established a Huh7 cell line stably expressing a replicon containing 3a core protein in 
a full-length 1b genomic replicon backbone. Core protein levels were decreased in the 
genotype 3a chimeric replicon (Fig 4.1b) and in the transient transfections (Fig 4.1a). 
However, NS5b levels were only slightly lower in the 3a core/ 1b replicon.  Also, the 
level of transient replication of the 1b replicon and 1b/3a core replicon was determined 
using a luciferase reporter-replicon construct that was transiently transfected into Huh7 
cells and monitored for replication levels for 72 hours. Transient replication levels were 
similar for 1b and 1b/3a core replicons (Fig 4.1c). 
 
4.4.2 HCV 3a core protein increases transcriptional activity from the SRE and 
LXRE transcription factor binding motifs.   
Our previous findings indicated that 3a core can increase the transcription of FAS 
in an SREBP-1 dependent manner.   SREBP-1c transcription is regulated by a positive 
feedback loop in which it contains an SRE responsive element along with a Liver X 
Receptor Responsive Element (LXRE).  LXR is also an important transcription factor for 
genes involved in lipid and cholesterol synthesis (Dif et al., 2006). We first examined the 
effect of core protein on the SRE and LXRE binding elements alone using a luciferase 
assay.  HCV-3a core significantly increased transcriptional activity from SRE in 
comparison to 1b core or control cells in both transient transfections and replicon 
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expressing cells.  Transcriptional activity from LXRE was also increased by 3a core 
protein, but to a lesser extent than SRE indicating a much stronger effect of 3a core 
protein on SREBP-1 (Fig. 4.2a, b). Interestingly, 1b core appeared to have a stronger 
effect on LXRE than 3a core.  Using deletions of the SRE and LXRE sequences (Fig. 
4.2c, d), we showed that 3a core had also increased SREBP-1c transcriptional activity in 
comparison to 1b core and the control by luciferase reporter assays.  This effect was 
evident using both transient core transfections (Fig. 4.2c) and the chimeric replicon 
expressing cells (Fig. 4.2d), with a slightly enhanced effect on SREBP-1c transcription in 
replicon expressing cells.  Deletion of the SRE and LXRE motifs resulted in significantly 
decreased transcriptional activity from the SREBP-1c promoter in control, 1b core and 3a 
core transiently transfected and replicon cells.  However, significantly increased SREBP-
1c promoter activity was not observed in the presence of 1b core or the 1b replicon, 
despite the increased activity from SRE or LXRE alone, suggesting that 1b core may not 
influence the SREBP-1c promoter in the same manner or to the same extent as 3a core.  
This result further emphasizes the role of 3a core in increasing transcription of lipid 
metabolism genes through SREBP-1c and also suggests a role for the LXR in mediating 
the effects of the HCV core protein. 
 
4.4.3 Processing of SREBP-1 is increased by the presence of HCV core protein.   
In addition to transcriptional regulation, SREBP-1 is regulated post-translationally 
by cleavage into a mature, 68 kDa nuclear localized transcription factor. Therefore, we 
wanted to examine the cleavage of SREBP-1 in the presence of 1b or 3a core proteins.  
Our experiments demonstrated HCV-3a core increased cleavage of SREBP-1 into the 
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mature form in both transient transfections (Fig. 4.3a) and in the chimeric 1b/3a replicon 
cells (Fig. 4.3b) than HCV-1b core. Increased processing and/or stabilization of the 
mature SREBP-1 may contribute to the increased transcriptional activity from the SRE 
that we have observed. 
 
4.4.4 Akt-1 and Akt-2 phosphorylation is increased in the presence of HCV core 
protein.    
As previous studies had shown that Akt activity is involved in modulating 
SREBP-1 activity (Porstmann et al., 2005), we wanted to examine the level of Akt 
phosphorylation in the presence of 1b or 3a core protein.  Three isoforms of Akt exist that 
have different effects on cell signaling.  Akt-1 is primarily involved in cell survival while 
Akt-2 is potentially involved in insulin resistance (Cho et al., 2001). Our results 
demonstrated an increased phosphorylation of the Ser-473 residue of Akt-1 in genotype 
3a core expressing cells in comparison to genotype 1b core expressing cells and both core 
proteins induced phosphorylation to a greater extent than the control cells (Fig. 4.4a, b).  
Similarly, a small increase in Ser-474 phosphorylation of Akt-2 was observed in the 
presence of genotype 3a and 1b core. (Fig. 4.4c, d).  Densitometry analysis from three 
experiments to calculate a ratio between total Akt-2 and phosphorylated Akt-2 showed 
increased Akt-2 phosphorylation in the presence of core protein. The increased 
phosphorylation of Akt-1 and Akt-2 by HCV core could be abrogated by a PI3K inhibitor 
LY294002, indicating that activation of both Akt-1 and Akt-2 by HCV core is through 
PI3K (Fig. 4.4). These results suggest a possible role of Akt-2 in modulation lipid 
metabolism by HCV core. 
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4.4.5 Inhibition of Akt activity causes decreased SREBP-1 activation by HCV core 
protein.   
Activity of Akt has been linked to the processing of SREBP-1c and inhibition of 
Akt also decreases SREBP-1 activity (Porstmann et al., 2005). As our previous 
experiments showed an increased amount of mature SREBP-1c in cells expressing HCV-
3a core, we wanted to examine whether inhibition of Akt also affected SREBP-1 activity 
in the presence of core protein.  Firstly, we examined the effect of Akt inhibition on the 
SREBP-1c promoter in the presence of HCV core proteins.  For this purpose, we 
inhibited Akt activity using the PI3K inhibitor LY294002 or an Akt isoform specific 
inhibitor AktVIII. Inhibition of PI3K by LY294002 and Akt-1 and/or Akt-2 by AktVIII 
in transiently transfected and replicon cells significantly inhibited SREBP-1c promoter 
activation by HCV core (Fig. 4.5). These results suggest both Akt-1 and Akt-2 are 
involved in SREBP-1c promoter activation by HCV core. 
To investigate whether Akt is also involved in activating SREBP-1 processing by 
HCV core, we again used LY294002. As shown in Fig. 4.3, treatment with LY294002 
drastically decreased mature SREBP-1 level in comparison to control-treated cells. 
Consistently, when we assayed the SRE-driven luciferase activity as a read-out of 
SREBP-1 activity, the PI3K inhibitor LY294002 significantly decreased SRE-driven 
transcriptional activity by HCV-1b or 3a core protein, as well as in control cells (Fig. 4.6, 
a and b).  Likewise, application of Akt inhibitor AktVIII at a lower, Akt-1 specific dose 
(58 nM) significantly decreased SRE-driven transcriptional activation by HCV core 
proteins either after transfection or in replicon cells. Interestingly, AktVIII inhibitor at the 
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higher concentration of 210 nM, which should suppress both Akt-1 and Akt-2, was much 
more effective in replicon cells than in transiently transfected cells (Fig. 4.5a, b). 
Plasmids expressing dominant negative Akt-1 or Akt-2 mutants were also used to inhibit 
Akt and both had a similar inhibitory effect on SRE activation (Fig. 4.5 c, d).  To further 
confirm the role of Akt, Akt-1 and Akt-2 knock down cells were created by stably 
transducing Huh7 cells with a lentivirus construct containing Akt-1 or Akt-2 specific 
shRNA.  When transfected with HCV core protein-expressing plasmids, cells with either 
Akt-1 or Akt-2 knocked down had significantly decreased transcriptional activity from 
SRE (Fig. 4.5e).  These results suggest that activation of Akt-1 and Akt-2 are involved in 
SREBP-1 activation by HCV core.  
 
4.5 Discussion 
 Clinical studies have shown that chronic HCV-3a infection leads to the 
development of steatosis in approximately 70% of cases.  Deregulation of lipid 
metabolism pathways in hepatocytes is believed to be a major mechanism for the 
development of steatosis. The mechanism by which HCV-3a can cause steatosis is not 
well understood.  Several studies have suggested a role for core and NS5a proteins of 
genotype 1b and 2a in changing lipid metabolism pathways that may contribute to 
steatosis observed in other genotypes.   
Our previous results have shown that genotype 3a core alone is able to up-regulate 
transcription of FAS in an SREBP-1 dependant manner.  Genotype 1b core was also able 
to upregulate FAS, but to a lesser extent. However, the mechanisms by which HCV core 
protein up-regulates FAS transcription are not clear. 
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In this study we sought to investigate mechanisms for the observed increase in 
FAS promoter activation by HCV core protein.  To do this we utilized two different 
models:  transiently transfected Huh7 cells expressing only the core protein, and stable 
HCV replicon expressing Huh7 cells containing either a genomic 1b replicon, or a 
chimeric 1b replicon containing the 3a core gene instead of the 1b core gene.  Cells 
expressing the HCV replicon have been widely used for HCV research as they express all 
of the HCV proteins as a result of HCV RNA replication (Pietschmann et al., 2002).  
We showed that the transcription activity from SRE was enhanced in the presence 
of genotype 3a core protein in comparison to genotype 1b core (Fig. 4.2, a).  This would 
explain that HCV-3a core expression resulted in significantly higher SREBP-1c promoter 
activity (Fig. 4.2, c and d). In the case of HCV-1b core, it could activate transcription 
driven by SRE when it was expressed alone after transient transfection, but not in 
genomic replicon cells (Fig. 4.2, a and b). Consequently, HCV-1b core did not up-
regulate SREBP-1c promoter when expressed alone or in replicon cells (Fig. 4.2, c and 
d). However, HCV-1b core was a stronger activator for LXRE-driven activity than HCV-
3a core. This is consistent with previous studies that have observed an effect on LXR 
activity by HCV-1b core protein (Moriishi et al., 2007; Waris et al., 2007). These results 
further reinforce the notion that HCV of different genotypes has different mechanisms in 
causing steatosis. 
SREBP-1 is translated as a larger precursor protein that is cleaved into its mature, 
nuclear localized and active form.  Genotype 1b core and genotype 3a core have both 
been shown to enhance cleavage of SREBP-1 (Waris et al., 2007). In this study, we have 
further demonstrated an enhanced level of SREBP-1 cleavage in the presence of 3a core 
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protein in comparison to 1b core. The increased amount of mature SREBP-1 in core 
expressing cells would explain the increased transcription from the SRE as well as FAS 
and SREBP-1c promoters that we have observed.  
Several studies have shown that HCV affects the PI3K/Akt signaling pathway.  
As Akt exists in at least three isoforms that vary in function, we examined the effect HCV 
type 1b and 3a core protein had on Akt-1 and Akt-2 specifically.  A greater effect on Ser-
473 phosphorylation of Akt-1 was observed in the presence of 3a core protein in 
comparison to 1b core.  Ser-474 phosphorylation of Akt-2 was also increased in the 
presence of both core proteins. Our results confirmed and expanded previous studies 
showing enhanced serine phosphorylation of Akt-1 by HCV core (Banerjee et al., 2008; 
Waris et al., 2007). Akt activity has been linked to the regulation of SREBP-1 cleavage 
and stability with an increased Akt activity resulting in increased SREBP-1 activity and 
increased expression of lipid metabolism genes (Porstmann et al., 2005). As such, we 
examined the role of increased Akt activity by HCV core and its effects on SREBP-1 
activity.  We showed that inhibiting Akt-1 and/or Akt-2by a number of methods indeed 
decreased SREBP-1c promoter activity as well as SREBP-1 processing and its activity as 
a transcriptional factor, indicating that increased activity of both Akt-1 and Akt-2 in the 
presence of the HCV core protein may play a role in enhancing lipid metabolism gene 
expression and contribute to the development of steatosis.  Although statistically 
significant, inhibition of Akt did not completely abolish the up-regulation of SREBP-1 by 
HCV core and as such it is likely that other mechanisms are also involved in this process. 
For example, Waris et al. have shown that oxidative stress in cells expressing HCV core 
87 
protein can cause increased SREBP-1 and -2 processing that also contributes to the 
alteration of lipid metabolism in HCV infected cells. 
The results of this study indicate an important role of increased Akt-1 and Akt-2 
activity in mediating the effects of the HCV core protein on the expression of genes 
involved in lipid metabolism.  In addition, this is the first study to examine the potential 
effects of HCV core on different isoforms of Akt.  Our results further elucidate the 
molecular mechanisms of steatosis associated with HCV infection. 
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Figure 4.1.  Generation and characterization of HCV chimeric replicon containing 
HCV-3a core.  A) Expression of core protein in transiently transfected Huh7 cells.  B) 
Expression of core and NS5b in 1b N replicon cells and 1b/3a core chimeric replicon 
cells. C) Transient replication of the 1b and 1b/3a core replicon in Huh7 cells. 
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Figure 4.2.  HCV-3a core protein increases transcriptional activity from the SRE 
and LXRE transcription factor binding motifs.  A) Transcription activity from SRE 
and LXRE in transiently transfected Huh7 cells expressing core protein.  B) Transcription 
activity from SRE and LXRE in replicon expressing cells. C) Deletion of SRE and LXRE 
promoter elements in SREBP-1c promoter in transiently transfected Huh7 cells 
expressing core protein.  D) Deletion of SRE and LXRE promoter elements in SREBP-1c 
promoter in replicon cells.  Data is representative of three separate experiments. 
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Figure 4.3. Cleavage of SREBP-1c is enhanced by HCV 3a core protein.  A) Cleavage 
of SREBP-1 in transiently transfected Huh7 cells. B) Cleavage of SREBP-1 in HCV 
replicon cells.  Cells were grown in DMEM with 1% FBS for 48 hours after transfection.  
50 µM LY294002 was added 16 hours prior to harvesting. Western blots shown are 
representative of three separate experiments.  Densitometry was determined by assessing 
band intensity on a LiCor Odyssey infrared scanning system and values were normalized 
to β-actin levels. 
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Figure 4.4.  Phosphorylation of Akt-1 and Akt-2 are increased in the presence of 
HCV core. A) Endogenous Akt-1 and phosphor-Akt-1 Serine-473 in HCV core 
transiently transfected Huh7 cells determined by western blot.  B) Endogenous Akt-1 and 
phospho-Akt-1 Serine-473 in HCV replicon expressing cells.  C) Total Akt-2 and 
phospho-Akt2 Serine-474 in HCV core transiently transfected Huh7 cells. D) Total Akt-2 
and phospho-Akt-2 Serine-474 in HCV replicon expressing cells.  50 µM LY294002 was 
added 16 hours prior to cell harvesting.  pAkt band intensities were normalized with total 
Akt band intensities.  Densitometry was determined using the Odyssey Imaging Software 
and is representative of 3 separate experiments. 
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Figure 4.5.  Inhibition of Akt causes decreased SREBP-1c transcriptional activity in 
the presence of HCV core protein.  A) Luciferase activity from the SREBP-1c promoter 
in HCV core transiently transfected cells.  B) Luciferase activity from the SREBP-1c 
promoter in HCV replicon expressing cells. Cells were treated with DMSO as a control. 
50 µM LY294002, 58 nM AktVIII for inhibition of Akt1 or 210 nM AktVIII for 
inhibition of Akt1 and Akt2 were added for 16 hours prior to harvesting.  
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Figure 4.6.  Inhibition of Akt activity results in decreased effect of HCV core protein 
on up-regulation of transcription from SRE.  A) Transcription activity from SRE in 
transiently transfected Huh7 cells treated with LY294002 and Akt VIII chemical 
inhibitors of Akt. 58 nM Akt VIII inhibits Akt-1; 210 nM Akt VIII inhibits Akt-1 and 
Akt-2. B) Transcription activity from SRE in replicon expressing cells treated with 
LY294002 and Akt VIII chemical inhibitors of Akt. C) Transcription activity from SRE 
in transiently transfected Huh7 cells expressing dominant negative Akt-1 or Akt-2.  D) 
Transcription activity from SRE in replicon cells expressing dominant negative Akt-1 or 
Akt-2.  E) Generation of Akt-1 and Akt-2 knock out cells.  Expression of Akt-1 or Akt-2 
in Huh7 cells selected for knock down of Akt-1 or Akt-2 by an shRNA in a lentiviral 
vector.  F) Transcription activity from SRE in transiently transfected cells that have Akt1 
or Akt2 knocked down via stable lentivirus transduction. Cells were treated with DMSO 
as a control where appropriate. 50 µM LY294002, 58 nM AktVIII for inhibition of Akt-1 
or 210 nM AktVIII for inhibition of Akt-1 and Akt-2 were added for 16 hours prior to 
harvesting.  Dominant negative Akt-1 or Akt-2 expressing plasmids were transfected into 
cells 48 hours before harvesting. 
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5.1 Abstract 
Transcriptional factor SREBP-1c (sterol regulatory element binding protein-1c) 
activates the transcription of lipogenic genes, including fatty acid synthase (FAS).  
Hepatitis C virus (HCV) infection is often associated with lipid accumulation within the 
liver, known as steatosis in the clinic.  The molecular mechanisms of HCV-associated 
steatosis are not well characterized.  Here, we showed that HCV non-structural protein-2 
(NS2) activated SREBP-1c transcription in human hepatic Huh-7 cells as measured by 
using a human SREBP-1c promoter - luciferase reporter. We further showed that sterol 
regulatory element (SRE) and liver X receptor element (LXRE) in the SREBP-1c 
promoter were involved in SREBP-1c activation by HCV NS2. Furthermore, expression 
of HCV NS2 resulted in up-regulation of FAS transcription. We also showed that FAS 
up-regulation by HCV NS2 was SREBP-1-dependent since deleting the SRE sequence in 
a FAS promoter and expressing a dominant-negative SREBP-1 abrogated FAS promoter 
up-regulation by HCV NS2. Taken together, our results suggested that HCV NS2 can up-
regulate the transcription of SREBP-1c and FAS and thus is likely a contributing factor 
for HCV-associated steatosis.  
 
5.2 Introduction 
Sterol regulatory element binding protein-1c (SREBP-1c) is a member of the 
basic-helix-loop-helix-leucine zipper family of transcription factors (Horton et al., 
2002;Eberle et al., 2004). SREBP-1c expression is regulated at the transcription level 
(Desvergne et al., 2006). For instance, liver X receptor (LXR) activates SREBP-1c 
transcription by binding to the LXR element (LXRE) sequences in the SREBP-1c 
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promoter (Yoshikawa et al., 2001;Dif et al., 2006;Tarling et al., 2004). SREBP-1c can 
also regulate its own transcription in a positive feed-back loop through binding to the 
sterol regulatory elements (SREs) in the SREBP-1c promoter (Amemiya-Kudo et al., 
2000). The newly synthesized, precursor SREBP-1c protein is bound to the endoplasmic 
reticulum (ER). Following proteolytic digestions, the amino-terminal domain is released 
and transported to the nucleus as an active transcriptional factor (Brown et al., 2000). The 
processed, mature SREBP-1 proteins are modified by phosphorylation by protein kinases, 
such as mitogen-activated protein kinase (MAPK), protein kinase A (PKA), and glycogen 
synthase kinase-3β (Roth et al., 2000;Lu and Shyy, 2006;Punga et al., 2006;Kotzka et al., 
1998). The impact of phosphorylation on the transcriptional activity of SREBP-1 is less 
clear. For instance, phosphorylation by MAPK appears to enhance the transcriptional 
activity of SREBP-1, whereas PKA phosphorylation suppresses the function of SREBP-1 
(Kotzka et al., 1998;Kotzka et al., 2000;Lu and Shyy, 2006). A major function of 
SREBP-1c is to activate genes involved in the synthesis of fatty acid and their 
incorporation into triglycerides and phospholipids (Horton et al., 2002;Eberle et al., 
2004). As such, abnormal higher levels of SREBP-1c will result in lipid accumulation in 
the liver and cause steatosis (Ferre and Foufelle, 2007). Fatty acid synthase (FAS) is a 
well established target gene of SREBP-1c (Latasa et al., 2000;Amemiya-Kudo et al., 
2002). 
Steatosis is an important clinical manifestation associated with hepatitis C virus 
(HCV) infection (Asselah et al., 2006). The development of steatosis in HCV infections 
is a complex process that likely involves both host and viral factors. As a major 
transcription factor for lipogenic gene expression, SREBP-1 may play a major role in this 
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process. For instance, HCV infection enhances the proteolytic processing of SREBP-1 
(Waris et al., 2007).  The expression of HCV core and non-structural protein-4B (NS4B) 
proteins also enhances SREBP processing and lipid accumulation (Waris et al., 2007;Kim 
et al., 2007;Yamaguchi et al., 2005).  Our previous research showed that HCV core 
protein can activate FAS promoter in an SREBP-1-dependent manner (Jackel-Cram et al., 
2007). Given the key role of SREBP-1c in hepatic steatosis, we investigated whether 
HCV NS2 protein may regulate SREBP-1c expression and thus be involved in causing 
steatosis. In this study, we showed that HCV NS2 protein increases SREBP-1c 
transcription, protein expression, and proteolytic processing.  We further showed that 
FAS transcription is also up-regulated by HCV NS2, as a consequence of SREBP-1c 
activation. Our results suggested that HCV NS2 is a contributing factor for HCV-
associated steatosis. 
 
5.3 Materials and methods 
 
5.3.1 Cloning and expression of the NS2 protein.  
The coding sequence of NS2 of HCV H77 (genotype 1a) was amplified from 
plasmid p90/FL (Kolykhalov et al., 1997) by polymerase chain reaction (PCR) and 
cloned into an expression vector pEF-myc with the elongation factor-1α promoter 
(Invitrogen). The resultant NS2 protein had a translation initiation codon and a myc-tag at 
the carboxyl-terminus (Fig.1). The plasmid sequence was confirmed by DNA sequencing. 
To demonstrate NS2 expression, Huh-7 cells were transfected with pEF-NS2-myc and 
pEF-myc vector by the calcium phosphate method followed by immunoblotting as 
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described (Jackel-Cram et al., 2007). As shown in Fig. 5.1, a myc-tag antibody 
(Invitrogen) recognized a protein of approximately 23 kDa after pEF-NS2-myc 
transfection, but not after vector transfection, indicating the expression of the myc-tagged 
NS2 protein. 
 
5.3.2 Luciferase assays 
 
 Dual luciferase assay (Promega) was done using the manufacturer’s protocol.  
Huh-7 cells were transfected using calcium phosphate precipitation as previously 
described and harvested 48 hours after transfection.  Huh-7 cells were transfected with 
HCV NS2-expressing plasmid or the vector control, together with a human SREBP-1c 
promoter - luciferase reporter (SREBP-1c-571-Luc-WT), kindly provided by Dr. Lefai 
(Dif et al., 2006).  A plasmid encoding the Renilla luciferase gene under the control of 
elongation factor -1α promoter was also included in the transfections as a control for 
luciferase assays as described (Oem et al., 2007).  To determine the involvement of 
LXRE and SRE, the two LXRE and two SRE sequences were eliminated by site-directed 
mutagenesis as described (Dif et al., 2006). The primer sequences were as follows (the 
mutated sequences were underlined): 5’-
GAGGGCCAGAGTCCGCCAGATTCCCCGGCA- 3’ and 5’ -
GGCGGAAGTCCGCTAGATTCCCCAACCCC- 3’ for LXRE, 5’ -
CCATTCAGCGCCGCGAGATAAAACTCGAGCCCCC- 3’ and 5’ - 
GGCCGCGCGCGCTTATCTCATGCCCGGCCCGC- 3’ for SRE, respectively. These 
mutant SREBP-1c promoter plasmids were confirmed by DNA sequencing and then used 
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in co-transfection experiment to determine the SREBP-1c promoter activity after HCV 
NS2 expression. 
 
5.3.3 Immunoblotting 
 
Transfected cells were lysed and loaded onto 10% gels for polyacrylamide gel 
electrophoresis.  The gels were transferred onto nitrocellulose membrane, blocked in 2% 
milk powder in PBS, and incubated with an anti-SREBP-1 antibody (Santa Cruz 
Biotechnology).  After washing, the blots were incubated in IRDye 680 goat anti-rabbit 
IgG secondary antibody (Li-Cor Biosciences).  As protein loading controls, the levels of 
β-actin were also determined using a β-actin-specific antibody (Cell Signaling 
Technology).  Blots were scanned on an Odyssey Infrared Imaging System (Li-Cor 
Biosciences).  Quantification of the density ratio of the precursor and mature SREBP-1 
proteins to β-actin within the same sample was performed using the Odyssey software 
(LI-COR Biosciences). 
 
5.3.4 RT-PCR.   
Total RNA was extracted from Huh-7 cells 48 hours after transfection with a 
plasmid expressing HCV NS2 or the plasmid vector by TriZol (Invitrogen) followed by a 
clean-up with RNeasy mini-columns (Qiagen).  After digestion with an RNase-free 
DNase-I (Ambion), cDNA was synthesized by reverse transcription and subjected to PCR 
amplification using FAS-specific primers (forward: 5’- 
GGTCTTGAGAGATGGCTTGC-3’ and reverse: 5’-AATTGGCAAAGCCGTAGTTG-
3’).  As a control, β-actin was amplified with primers (forward: 5’-
AGCGGGAAATCGTGCGTG-3’ and reverse: 5’-CAGGGTACATGGTGGTGCC-3’).  
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The PCR products were resolved in agarose gels and analyzed by densitometry using the 
software Quantity One (BioRad). 
 
5.4 Results 
 
 
5.4.1 HCV NS2 protein activates the SREBP-1c promoter.   
To investigate whether HCV NS2 protein can influence SREBP-1c transcription, 
we measured SREBP-1c promoter activity by using an SREBP-1c promoter - luciferase 
reporter.  Huh-7 cells were transfected with HCV NS2-expressing plasmid or the vector 
control, together with a human SREBP-1c promoter - luciferase reporter (SREBP-1c-571-
Luc-WT, Fig. 5.2a. As shown in Fig. 5.2b, expression of HCV NS2 resulted in more than 
four-fold induction in SREBP-1c promoter activity in comparison to vector control (Fig. 
5.2b, RLU: 207±64 and 1036±143 for vector and NS2, respectively, P=0.006 as per a 
Student’s t test), suggesting the HCV NS2 activates SREBP-1c promoter.  
 
5.4.2 LXRE and SRE motifs in the SREBP-1c promoter are required for SREBP-1c 
activation by HCV NS2.   
The human SREBP-1c -571 promoter sequence contains two LXREs (at positions 
-311/-296 and -260/-245) and two SREs (at positions -228/-218 and -127/-117) (Fig. 
5.2a) (Dif et al., 2006;Tarling et al., 2004). To determine whether the LXRE and SRE 
sequences are involved in SREBP-1c promoter up-regulation by HCV NS2, the two 
LXRE and two SRE sequences were eliminated by site-directed mutagenesis. As shown 
in Fig. 5.2c, elimination of either LXRE or SRE motifs in the SREBP-1c promoter 
resulted in significantly lower SREBP-1c promoter activity in comparison to the wild-
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type promoter after HCV NS2 expression (Fig. 5.2c, RLU: 1070±63, 557±31, and 
432±52 for wild-type, ΔLXREs, and ΔSREs, respectively; wild-type vs. ΔLXRE, 
P=6.7x10-6, wild-type vs. ΔSRE, P=2.2x10-6). Elimination of both LXRE and SRE motifs 
in the SREBP-1c promoter further decreased SREBP-1c promoter activation by HCV 
NS2 (Fig. 5.2c, RLU: 180±21 for ΔLXRE/ΔSRE; wild-type vs. ΔLXRE/ΔSRE, 
P=4.9x10-7, ΔLXRE vs. ΔLXRE/ΔSRE, P=3.2x10-6, and ΔSRE vs. ΔLXRE/ΔSRE, 
P=1.5x10-4). These results demonstrated that the LXRE and SRE motifs in the SREBP-1c 
promoter are required for SREBP-1c promoter activation by HCV NS2. 
To directly demonstrate whether HCV NS2 could activate transcription driven by 
LXRE or SRE motifs, we used luciferase reporters containing two copies of the LXRE 
sequences (TGACCGGCAGTAACCC, pLXRE-Luc) (Joseph et al., 2002) or three copies 
of SRE sequences (ATCACCCCAC, pSRE-Luc) (Amemiya-Kudo et al., 2002), 
respectively. As shown in Fig. 5.2d, expression of HCV NS2 was associated with 2.8- or 
5.2-fold induction of LXRE- or SRE-driven luciferase expression in comparison to vector 
control. Taken together, these results indicated that HCV NS2 increases SREBP-1c 
transcription through SRE and LXRE elements in the SREBP-1c promoter. 
 
5.4.3 HCV NS2 enhances SREBP-1 protein expression and proteolytic cleavage.   
To demonstrate whether the increased SREBP-1c transcription by HCV NS2 
resulted in enhanced SREBP-1c protein expression and proteolytic cleavage, the amount 
of SREBP-1c protein was determined by immunoblotting using the lysates of Huh-7 cells 
transfected by plasmid expressing HCV NS2 or the plasmid vector control and an 
SREBP-1-specific antibody (Santa Cruz Biotechology). As shown in Fig. 5.2e, HCV NS2 
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expression was associated with increased levels of both precursor and mature SREBP-1 
proteins. These results demonstrated that HCV NS2 enhances SREBP-1 protein 
expression and proteolytic cleavage.       
 
5.4.4 HCV NS2 enhances FAS transcription in an SREBP-1c dependent manner.   
Since FAS is a target gene of SREBP-1c, we were interested in determining 
whether HCV NS2 could also activate FAS transcription. For this purpose, the FAS 
transcript level was determined by reverse transcription (RT)-PCR. As shown in Fig. 
5.3a, NS2 expression was associated with three-fold induction of FAS transcripts in 
comparison to vector control.  This was confirmed by luciferase assay results when a 
FAS promoter - luciferase reporter (Swinnen et al., 1997;Jackel-Cram et al., 2007) was 
used to measure FAS promoter activity after NS2-expressing or vector plasmid 
transfection (Fig. 5.3b; RLU: 93±4 and 205±8 for vector and NS2, respectively, 
P=0.002).  Furthermore, when the SREBP-1c binding element (SRE) was deleted from 
the FAS promoter, HCV NS2 was no longer able to activate FAS promoter (Fig. 5.3b; 
RLU: 205±8 and 16±1 for NS2+FAS-wild-type and NS2+FAS-dSRE, respectively, 
P=0.0007), suggesting FAS promoter up-regulation by HCV NS2 is through the SRE 
sequence. To further confirm the role of SREBP-1c, we used a dominant negative (DN) 
SREBP-1 plasmid in a co-transfection experiment as described previously (Jackel-Cram 
et al., 2007).  As shown in Fig. 5.3c, while plasmid vector did not have an effect on FAS 
activation by HCV NS2, transfection of DN-SREBP-1 significantly abolished FAS 
activation by HCV NS2. These results indicated that HCV NS2 enhances FAS 
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transcription in an SREBP-1-dependent manner, probably as a consequence of SREBP-1c 
activation. 
 
5.5 Discussion 
The functions of HCV NS2 protein are not well understood since limited studies 
have been performed to understand the role of NS2 in HCV-host interactions. In this 
study, we showed that HCV NS2 may be a contributing factor to intracellular lipid 
accumulation by up-regulating the transcription of SREBP-1c through LXRE and SRE 
motifs in the SREBP-1c promoter. We further showed that HCV NS2 protein expression 
resulted in increased levels of precursor and processed SREBP-1 proteins. As a target 
gene of SREBP-1c, we showed that HCV NS2 can activate FAS transcription in an 
SREBP-1-dependent manner. These results indicate that HCV NS2 enhances SREBP-1c 
functional activity.  
Since phosphorylation of SREBP-1 may also play a role in modulating its activity, 
we attempted to characterize whether HCV NS2 alters SREBP-1c phosphorylation. 
However, we did not detect any discernible changes in SREBP-1 phophorylation after 
HCV NS2 expression (data not shown; completed by Jackel-Cram). Since it has been 
demonstrated that HCV infection increases SREBP-1 phosphorylation (Waris et al., 
2007), it would be interesting to determine which HCV proteins are responsible for the 
enhanced SREBP-1 phosphorylation.  
The exact mechanisms of how HCV NS2 activates SREBP-1c are not clear. HCV 
NS2 is localized in the ER with no nuclear localization (Franck et al., 2005; Kim et al., 
1999). This suggests that HCV NS2 itself is unlikely a transcriptional factor which can 
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directly activate SREBP-1c transcription. Further investigations are required to study this 
issue.     
Our experimental approach was to express HCV NS2 protein in Huh-7 cells after 
plasmid transfection. It would be interesting to study the modulation of lipid metabolism 
by HCV NS2 protein in the context of HCV infection. However, this might not be readily 
achievable since NS2 is essential for HCV virus morphogenesis (Pietschmann et al., 
2006;Yi et al., 2007).  
In conclusion, our study identified a novel functional role of HCV NS2 protein in 
modulating lipid metabolism, which increased our understanding of the molecular 
mechanisms of HCV-associated steatosis. 
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Figure 5.1. Expression of HCV NS2 protein. The coding sequence of HCV H77 NS2 
was cloned into an expression vector pEF-myc, generating pEF-NS2-myc as shown in the 
upper panel. Expression of HCV NS2 was demonstrated in Huh-7 cells after transfection 
with the pEF-NS2-myc plasmid using a myc-tag antibody by immunoblotting analysis in 
the lower panel. Plasmid pEF-myc vector was used as a control. Experiment by Oem. 
115 
Figure 5.2. Activation of SREBP-1c by HCV NS2 protein.  A) Human SREBP-1c 
promoter reporter constructs. A human SREBP-1c promoter (-571) - luciferase reporter 
as well as the locations of liver X receptor elements (LXREs) and sterol regulatory 
elements (SREs) in the promoter are shown. Also shown are three mutant SREBP-1c 
promoter reporters without the two LXREs, the two SREs, or both. B) Activation of 
SREBP-1c promoter by HCV NS2. Huh-7 cells were transfected with HCV NS2-
expressing plasmid or the plasmid vector, together with an SREBP-1c promoter - 
luciferase reporter. Luciferase assay was performed 48 hours after transfection to 
determine the SREBP-1c promoter activity. The statistical differences between the 
samples were demonstrated as ** if p ≤ 0.01. C) Activation of SREBP-1c promoter by 
HCV NS2 requires LXRE and SRE sequences. Huh-7 cells were transfected with HCV 
NS2-expressing plasmid or the plasmid vector, together with wild-type or mutant 
SREBP-1c promoter - luciferase reporters. Luciferase assay was performed 48 hours after 
transfection. The statistical differences were demonstrated as *** if p ≤ 0.001.  D) 
Activation of LXRE- and SRE-driven transcription by HCV NS2. Huh-7 cells were 
transfected with a plasmid expressing HCV NS2 or the plasmid vector, together with 
pLXRE-Luc or pSRE-Luc. Luciferase assay was performed 48 hours after transfection. 
The statistical differences were demonstrated as ** if p ≤ 0.01 or *** if p ≤ 0.001.  E) 
HCV NS2 enhances SREBP-1c protein expression and proteolytic processing. Huh-7 
cells were transfected with HCV NS2-expressing plasmid or the plasmid vector. In the 
upper panel, the expression of myc-tagged NS2 protein was confirmed by 
immunoblotting using a myc-tag antibody. The precursor and mature SREBP-1 protein 
levels were determined using an SREBP-1-specific antibody. The level of β-actin was 
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demonstrated by a β-actin antibody. The intensity of the protein bands quantified by the 
Odyssey Infrared Imaging System (LI-COR Biosciences) was given under the 
corresponding protein bands. The relative levels of precursor and mature SREBP-1 after 
vector or NS2-expressing plasmid transfection were presented as the ratio of SREBP-1 
proteins to β-actin in a graph in the lower panel.  Experiments completed by Jackel-
Cram. 
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Figure 5.3. Activation of fatty acid synthase (FAS) transcription through SREBP-1c 
by HCV NS2 protein.  A) Activation of FAS transcription by HCV NS2. FAS transcript 
levels were determined by RT-PCR using FAS-specific primers in Huh-7 cells 48 hours 
after transfection with a plasmid expressing HCV NS2 or the vector control.  As a 
control, the level of β-actin was also determined.  The PCR products were analyzed by 
agarose gel electrophoresis in the upper panel followed by densitometry analysis shown 
in a graph in the lower panel. The statistical differences were demonstrated as * if p ≤ 
0.05.   B) Activation of FAS promoter by HCV NS2. Huh-7 cells were transfected with 
HCV NS2-expressing plasmid or the vector control, together with wild-type or SRE-
deleted FAS promoter - luciferase reporters. Luciferase assay was performed 48 hours 
after transfection to determine the FAS promoter activity. The statistical differences were 
demonstrated as ** if p ≤ 0.01 or *** if p ≤ 0.001.  C) Dominant-negative (DN) SREBP-
1 abrogated FAS activation by HCV NS2. Huh-7 cells were transfected with a plasmid 
expressing HCV NS2 or the plasmid vector, a wild-type FAS promoter - luciferase 
reporter, together with pcDNA3.1(+) vector or a plasmid expressing DN-SREBP-1. 
Luciferase assay was performed 48 hours after transfection. The statistical differences 
were demonstrated as * if p ≤ 0.05 or NS for not significant.  Experiments by Oem. 
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6.0 DISCUSSION AND CONCLUSIONS 
 Infection with HCV is very serious and life threatening with limited treatment 
options.  The virus primarily infects hepatocytes and it is one of the leading causes of 
liver disease in the world.  One of the primary roles of the liver is the metabolism of 
triglycerides and cholesterol and, as such, it is unsurprising that HCV infection alters 
lipid metabolism processes within hepatocytes.  A clear association was revealed between 
the development of steatosis and infection with HCV (Mihm et al., 1997). Approximately 
50% of HCV infected individuals have steatosis, compared with only 20% of the 
uninfected population.  Steatosis, although largely asymptomatic, is considered a 
precursor to the development of further liver disease such as hepatitis, fibrosis and 
cirrhosis.   The presence of steatosis is also known to decrease the chance of responding 
successfully to interferon therapy. Examining the mechanisms by which HCV causes 
steatosis could provide important information on how to slow the progression of liver 
damage or increase treatment outcomes.  Interestingly, infection with genotype 3 HCV 
appears to be more strongly associated with the development of steatosis and it may have 
a direct cytopathic effect on infected hepatocytes that results in the development of 
steatosis  (Rubbia-Brandt et al., 2000).  Exactly how and why there is a difference 
between genotype 3 and other genotypes is not fully understood.  As such, determining 
the mechanisms for this difference was one of the main objectives of this research. 
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6.1 Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: 
genotype 3a has a stronger effect than genotype 1b-core 
Previous HCV research has focused on genotype 1 infection due to the increased 
prevalence of this genotype and the difficulty in successfully treating patients infected 
with it.  Very little information was available on genotype 3 infection, especially any 
molecular aspects of the virus that could account for the differences observed in treatment 
response and association with steatosis.  Furthermore, very little was known about how 
HCV caused changes in lipid metabolism.   It was clear, however, that the core protein 
was the likely culprit, as it was known to associate with lipid droplets in hepatocytes 
(Barba et al., 1997).  Core protein could also bind to apolipoprotein AII and decrease the 
activity of MTP, thereby inhibiting secretion of VLDL (Sabile et al., 1999; Perlemuter et 
al., 2002).  As such, it was necessary to first characterize the genotype 3a core protein to 
ascertain whether it acted in a similar manner to genotype 1 core protein.  The genotype 
3a core gene was cloned from infected patient serum and into an expression plasmid for 
further examination.  Subcellular localization using confocal microscopy showed a 
distinct localization of core protein of both genotypes on lipid droplets in transiently 
transfected Huh-7 cells.  This was the first study to show that the genotype 3a core 
protein was also able to localize on lipid droplets, an important first step in characterizing 
the genotype 3a core protein.  Although the methodologies used were not sensitive 
enough to reveal a difference, research done by other groups has subsequently shown that 
the core protein is able to change the distribution of lipid droplets within hepatocytes 
(Boulant et al., 2008).  Core protein is also able to increase the amount and size of lipid 
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droplets, and this effect is even more pronounced in the presence of genotype 3a core 
protein (Abid et al., 2005; Piodi et al., 2008; Jhaveri et al., 2008). 
Since studies with the genotype 1 core protein had identified the sequence motifs 
responsible for lipid droplet binding (Hope and McLauchlan, 2000; Hope et al., 2002; 
McLauchlan et al., 2002; Suzuki et al., 2005), it was necessary to determine if the same 
sequence motifs were responsible for localization of the 3a core protein on lipid droplets.  
Site- directed mutatgenesis directed at the proline knot region, which mimics a lipid 
droplet localization motif in plant oleosin protein, was able to reduce lipid droplet 
localization of both 1b and 3a core proteins.  Deletion of the YATG sequence in 1b core 
or FATG in 3a core was also able to reduce lipid droplet localization.  These results 
suggest that similar sequences are involved in lipid droplet localization of both proteins. 
In order to determine if there were any functional differences between the 
genotype 1 and genotype 3a core proteins that influenced the lipid pathways of 
metabolism, the transcriptional activation of FAS was examined.  A previous study by Su 
et al. had discovered a potential role for SREBP in HCV pathogenesis and replication 
during chimpanzee infection using microarray analysis (Su et al., 2002).  FAS 
transcription is mediated by SREBP and it is one of the key enzymes responsible for the 
production of triglycerides in hepatocytes.  Therefore, up-regulation of the transcription 
of FAS could explain how HCV infection causes increased lipid in hepatocytes.  Using a 
luciferase reporter assay with the FAS promoter, an almost two-fold increase in FAS 
transcription was observed in the presence of the 3a core protein in comparison to 1b 
core.  Unsurprisingly, 1b core also increased FAS transcriptional activity, but not to the 
same extent as 3a core protein.  In addition, a dominant negative mutant of SREBP-1 was 
126 
able to completely inhibit the effect of the core proteins on FAS promoter activity, 
validating the hypothesis that the effect HCV core has on lipid metabolism is mediated 
via increased SREBP-1 activity.  This was the first study to show a potential mechanism 
for the differences observed between genotype 1b and 3a core proteins in causing 
increased triglyceride accumulation and steatosis. 
To further examine how FAS promoter activity was being up-regulated by the 
core protein, it was necessary to determine if the lipid droplet localization of the core 
proteins played a role.  The mutant 1b and 3a core proteins were used in the same 
luciferase reporter assay for FAS promoter activity.  There were no significant 
differences observed with the proline knot mutations, but deletion of the FATG sequence 
in 3a core was able to significantly decrease FAS up-regulation.  The phenylalanine 
residue present in this sequence in 3a core is a tyrosine residue in 1b core and it is not 
conserved in the 3a core gene.  Site-directed mutatgenesis was used to create a 3a core 
protein containing the tyrosine residue in place of the wild type phenylalanine.  This 
mutant reduced the up-regulation effect on FAS in comparison to the wild type 3a core 
protein, suggesting that this amino acid could be very important to the development of 
steatosis in HCV infection with genotype 3a.  Subsequently, Hourioux et al. also showed 
that this particular phenylalanine residue in the 3a core protein was able to induce 
triglyceride accumulation in hepatocytes, confirming its relevance in the development of 
steatosis by genotype 3a core (Hourioux et al., 2007).  Other groups have also examined 
whether specific polymorphisms in the genotype 3a core protein could be associated with 
steatosis.  Jhaveri et al. identified two residues at positions 182 and 186 in the 3a core 
protein that correlated with the presence of steatosis in HCV genotype 3a infected 
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patients. When these residues were mutated, increased lipid levels were no longer 
observed in an in vitro model (Jhaveri et al., 2008). However, Piodi et al. was unable to 
identify a specific amino acid residue(s) that could explain the development of steatosis 
in genotype 3a infection.  Both studies compared patients with and without steatosis 
infected with genotype 3 to try to explain why some individuals with genotype 3 
infection do not develop steatosis.  Their studies suggested that the development of 
steatosis may not be as simple as a polymorphism at one or more amino acid residues in 
the core proteins (Piodi et al., 2008).  This is not surprising because increased SREBP-1 
and/or FAS activity does not necessarily result in the development of steatosis because it 
is a complex process.  Host factors may still play a role in the development of steatosis, 
and other HCV proteins may also be involved in altering lipid metabolism. 
 
6.2 Hepatitis C virus genotype 3a core protein enhances sterol response element 
binding protein-1 transcription and cleavage via increased protein kinase B/Akt 
activity 
The next objective of this research was to further examine the role of SREBP-1 in 
mediating the effects of genotype 1b and 3a core proteins on lipid metabolism.  To do 
this, a HCV chimeric replicon expressing cell line was developed that contained the 3a 
core gene in a 1b HCV backbone.  Replicon cell lines represent an important in vitro 
model for the study of HCV replication and pathogenesis.  They contain the positive 
sense HCV RNA genome that stably replicates and produces the negative strand genome 
as well as all of the HCV proteins. However, with the exception of the JFH-1 HCV 
replicon and its derivatives, the replicon cell lines do not produce infectious viral 
128 
particles.  The replicon system provides a more accurate representation of infection 
within cell culture than transient transfection experiments that over-express one or more 
of the HCV proteins.  Replicon cell lines were used in the second study in order to 
determine how the presence of all of the HCV proteins could influence the cell signaling 
pathways being examined to ensure that the results obtained were valid and accurate.  In 
addition, similar experiments employing transient transfections when only the core 
proteins were expressed confirmed that the core protein was the primary mediator of the 
effects observed.  
As previously discussed, SREBP-1 is activated when sterol levels are low or when  
insulin is present.  Once cleaved, it is translocated into the nucleus and binds to the Sterol 
Response Element (SRE) sequence TCACNCCAC in its own promoter as well as in 
many different genes involved in lipid metabolism.  A luciferase reporter under the 
control of the SRE was used to determine the activity from the SRE in the presence of 1b 
or 3a core protein.  Consistent with FAS transcriptional activity, an increased level of 
activity from the SRE was observed in the presence of 3a core proteins in comparison to 
1b core in both transient transfections and replicon cells.  In contrast, no significant 
difference was observed using the Liver X Receptor Element (LXRE) in the same 
experiments.  LXR is another transcription factor that controls the expression of various 
genes involved in lipid metabolism, including SREBP-1, and it may act together with 
SREBP-1 upon insulin activation  (Chen et al., 2004).  To further confirm the role of 
SRE, the SREBP-1 promoter was used in luciferase assays with the core protein.  Upon 
deletion of the SRE or LXRE, or both binding elements, transcriptional activity was 
decreased, suggesting that although both binding elements play a role in transcriptional 
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activation in the presence of core, only SREBP-1 activity is significantly increased by 3a 
core protein.  Moriishi et al. also observed an involvement of LXR in increasing SREBP-
1c promoter activity in the presence of HCV 1b core protein (Moriishi et al., 2007).  
Interestingly, another study that examined the level of SREBP-1c mRNA in liver biopsies 
from chronically infected HCV patients concluded that there was no significant 
difference in SREBP-1c mRNA levels between infected and uninfected liver samples.  
One possible explanation for the discrepancy between this study and other in vitro and 
chimpanzee studies that have shown increased SREBP-1 is that this study examined 
chronically infected liver tissue, rather than those undergoing acute infection.  It is 
possible that the influence of HCV on lipid metabolism is different during different stages 
of infection.  Regardless, FAS mRNA levels were higher in HCV infected patients with 
steatosis and insulin resistance, suggesting that FAS up-regulation may be important 
throughout HCV infection and that other mechanisms may regulate FAS during chronic 
infection (McPherson et al., 2008). 
Although increased activity from the SRE can indicate increased activity of 
SREBP-1, it was necessary to examine how this increased activity of SREBP-1 was 
occurring.  Since processing of SREBP-1 into its mature form is critical for its role as a 
transcription factor, it was important to examine the processing of SREBP-1 in the 
presence of the core proteins.  A dramatic difference was observed in the amount of 
processed or mature SREBP-1 in the presence of 3a core protein in comparison to 1b core 
processing.  This result suggests that the mechanism by which 3a core activates SREBP-1 
activity is via increasing the processing or stability of mature SREBP-1.  Waris et al. 
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observed a similar effect on SREBP using both the JFH-1 cell culture system and the 3a 
core protein alone (Waris et al., 2007). 
Despite this information, the exact mechanism for the increased activity of 
SREBP-1 in the presence of core proteins remains unclear.  Recent studies have 
suggested that the processing of SREBP-1 may be regulated partially by Akt, an 
important cellular signaling kinase involved in insulin signaling and gluconoegenesis.  
Inhibition of Akt using a chemical inhibitor, LY294002, also inhibited processing and 
activity of SREBP-1 (Fleischmann and Iynedjian, 2000; Porstmann et al., 2005).  Several 
studies have shown an increased activity of Akt in the presence of core protein or in 
replicon cells; however, others have shown a decrease on Akt activity (Mannova and 
Beretta, 2005; Waris and Siddiqui, 2005; Waris et al., 2007; Yao et al., 2004; Kawaguchi 
et al., 2004; Miyamoto et al., 2007). Our study showed an increased serine 
phosphorylation of Akt-1 in the presence of either 1b core or 3a core.  We were also 
interested in the potential role of Akt-2 in the increased processing of SREBP-1.  Akt-2 is 
putatively involved primarily in insulin signaling (Dummler et al., 2006).  Akt-2 
phosphorylation of serine-474 was consistently, but not significantly, increased in the 
presence of the 1b or 3a core protein.  Inhibition of Akt-2 by a dominant negative mutant 
was also able to decrease SRE activity.  As such, Akt-2 may be important in mediating 
the effect of the core protein on lipid metabolism, but more research is needed to 
determine its exact role.  This is the first study to suggest a role for Akt2 in the 
pathogenesis of HCV. 
The next part of this study was to determine if inhibition of Akt-1 or Akt-2 could 
impair SREBP-1 activation by the core proteins.  To measure this we used the luciferase 
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reporter assay with the SRE binding element.  We inhibited Akt with the chemical 
inhibitor LY294002 or the isoforms specific inhibitor Akt VIII.  We also used dominant 
negative mutants of Akt-1 or Akt-2 and knock out cell lines for Akt-1 or Akt-2.  All of 
these approaches resulted in the inhibition of SREBP-1 activity to some extent, with the 
LY294002 inhibitor having the greatest effect.  The impairment of SREBP-1 activity was 
not complete though, and likely other mechanisms such as ER or oxidative stress in the 
presence of HCV can also influence SREBP-1 activity (Waris et al., 2007). 
This study identified one mechanism of how the 1b and 3a core proteins are able 
to enhance triglyceride synthesis via increased SREBP-1 activity.  The enhancement of 
SREBP-1 activity in vitro could help to explain how HCV 1b, and especially HCV 3a, are 
contributing to the development of steatosis in vivo.  It would be interesting to repeat this 
work using the JFH-1 infectious cell culture system to confirm that the same effect on 
lipid metabolism occurs during full HCV infection in cell culture.  As JFH-1 is a 
genotype 2a virus, chimeric viruses containing 1b or 3a genes would need to be 
developed and characterized.  Several studies have shown that this is possible, although 
virus production is much less than wild type JFH-1. This could become a problem when 
attempting to compare the effects of different chimeric viruses on lipid metabolism 
(Pietschmann et al., 2006).  However, one group has successfully developed a chimeric 
virus that produces high levels of infectious virus expressing 2a or 3a core proteins and 
could be useful for these studies (Gottwein et al., 2007). 
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6.3 Activation of sterol regulatory element-binding protein 1c and fatty acid 
synthase transcription by hepatitis C virus non-structural protein 2 
In the last part of this study, we hypothesized that other HCV proteins might be 
involved in altering lipid metabolism during infection.  Miyanari et al. showed that core 
proteins recruit non-structural proteins (NS3, NS4ab, NS5a, NS5b) to the surface of lipid 
droplets for assembly and production of infectious virus particles, suggesting that non-
structural proteins may also play a role in altering lipid metabolism.  Recently it has been 
determined that HCV NS2 protein is critical for the assembly and production of 
infectious virus (Jones et al., 2007; Jirasko et al., 2008).  Very little is known about 
whether or not NS2 plays a role in HCV pathogenesis.  As such, we investigated whether 
the genotype 1b NS2 protein could influence the same lipid metabolism pathways that the 
core protein was able to. 
In order to examine the role of NS2 in lipid metabolism, we first looked at its 
ability to activate the promoter of SREBP-1c using the same luciferase reporter system as 
used previously.  Surprisingly, the NS2 protein was able to significantly enhance 
transcription from the SREBP-1c promoter compared to the control.  In addition, deletion 
of the SRE and LXRE binding elements in the SREBP-1c promoter significantly 
inhibited the ability of NS2 to increase the promoter activity of SREBP-1c.  This was the 
first evidence that had been presented on a role of NS2 protein in the enhancement of 
lipid metabolism in vitro. 
The increased activity of the SREBP-1c promoter suggested that the level of 
SREBP-1 protein and its mature form could also be increased in the presence of NS2.  As 
such, we examined the level of precursor and mature SREBP-1 protein in the presence of 
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NS2 using immunoblotting.  We found that the level of both the precursor and mature 
SREBP-1 was increased by NS2.  This increase could explain the increased 
transcriptional activity from the SREBP-1c promoter. 
As previously mentioned, FAS transcription is regulated by SREBP-1.  We 
examined the amount of FAS mRNA in cells expressing NS2 and we found that the level 
of FAS mRNA was significantly enhanced.  In addition, luciferase reporter assays using 
the FAS promoter revealed an enhanced level of activity from the FAS promoter in the 
presence of NS2, confirming the RT-PCR results.  This effect on FAS transcription was 
determined to be dependent on the SREBP-1. 
This study has demonstrated a novel role for NS2 protein in altering lipid 
metabolism by enhancing SREBP-1c activity in a similar manner to the core protein. 
Both NS5a and NS4a have been implicated in altering lipid metabolism in vitro and so it 
is not surprising that NS2 could have a similar effect on lipid metabolism that may be 
indirect or non-specific (Park et al., 2009; Shi et al., 2002). NS2 localizes to the ER 
membrane along with the core protein and several other HCV proteins.  SREBP-1 is 
bound to the ER membrane until it is cleaved and enters the nucleus to act as a 
transcription factor.  The localization of the HCV proteins to the ER could be positively 
influencing the cleavage of SREBP-1 regardless of the levels of lipid in the cells.  More 
studies will be necessary to determine if the HCV proteins are causing ER stress or if 
they are activating the regulators of SREBP-1 cleavage: SCAP, Insig, S1P and S2P.  
Several studies have shown other HCV non-structural proteins as having a role in altering 
lipid metabolism (Park et al., 2009; Shi et al., 2002; Waris et al., 2007).  The involvement 
of multiple HCV proteins in altering lipid metabolism pathways suggests that these 
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pathways are very important to the virus life cycle and HCV has evolved multiple 
mechanisms to exploit these pathways to use to it’s advantage. 
 
6.4 General conclusions: 
 
1.  HCV enhances lipid production in vitro via increased activity of SREBP-1. This 
effect may partially explain how HCV infection causes the development of steatosis 
during chronic infection. 
 
2.  HCV genotype 3a core protein has a greater effect on lipid metabolism than 
genotype 1b in vitro, suggesting that the 3a core protein may be responsible for the 
development of steatosis in genotype 3a-infected individuals. 
 
3.  The NS2 protein may also play a role in the development of steatosis during HCV 
infection. 
 
Throughout the course of this research, it has become more and more apparent 
that alteration of lipid metabolism is very important for the life cycle hepatitis C virus.  
HCV appears to exploit the VLDL assembly and secretion pathway for its own assembly 
and secretion, thereby producing virus particles bound to host proteins that can evade the 
immune system and utilize host lipoprotein receptors for entry and infection (Gastaminza 
et al., 2008; Burlone and Budkowska, 2009; Huang et al., 2007). Furthermore, inhibition 
of FAS activity using chemical inhibitors can reduce HCV production and entry, 
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suggesting that the enhancement of FAS may be critical to the life cycle of the virus 
(Yang et al., 2008).  The information gained from the research presented in this thesis, as 
well as the current knowledge on lipid metabolism dysfunction in HCV infection, will 
help to develop new treatments for HCV infection (Amemiya et al., 2008; Fujita et al., 
2006; Bader et al., 2008). 
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